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The aim of this study was to investigate macrophage interactions with electrospun 
scaffolds and quantify the expression of vital angiogenic growth factors in vitro. This study 
will further help in evaluating the potential of these electrospun constructs as vascular 
grafts for tissue repair and regeneration in situ. Human peripheral blood macrophages were 
seeded in serum free media on electrospun (10 mm) discs of polydioxanone (PDO), elastin 
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and PDO:elastin blends (50:50, 70:30 and 90:10). The growth factor secretion was 
analyzed by ELISA. Macrophages produced high levels of vascular endothelial growth 
factor (VEGF) and acidic fibroblast growth factor (aFGF). Transforming growth factor 
beta-1 (TGF-β1) secretion was relatively low and there was negligible production of basic 
fibroblast growth factor (bFGF). Histology revealed direct correlation between cell 
infiltration into scaffolds and the PDO concentration. There was greater macrophage 
infiltration through fibrous networks of the PDO and 90:10 scaffolds. Therefore, it can be 
anticipated that these scaffolds will support tissue regeneration and angiogenesis.
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INTRODUCTION 
 
Macrophages are known to play a central role in implant healing, vascularization and 
integration into the native tissue. It has been established from previous studies that the fate 
of a tissue engineered implant depends upon the kind of macrophage response it elicits [1].  
Tissue regeneration begins with phagocytosis of debris and extracellular matrix (ECM) 
remodeling and reorganization through enzymes released by the macrophage which 
include proteinase, collagenase, elastase and hyaluronidase [2]. The second step involves 
cell recruitment, migration, proliferation and ECM formation via the spectrum of cytokines 
produced by the macrophage. The third and final step of tissue regeneration is 
angiogenesis, a process by which new capillary blood vessels are generated from a pre-
existing vascular system. Angiogenesis is fundamental to wound healing, reproduction and 
embryonic development [2]. It results from stimulation of endothelial cells, which causes 
them to proliferate and migrate towards the source of pro-angiogenic molecules. On 
reaching a certain appropriate density, junctions between endothelial cells are formed, 
components of ECM are produced and a new basal membrane is formed [3] . The 
endothelial cells then progress to form a hollow tube. All steps in this transformation are 
induced by the myriad of growth factors derived from the macrophage. 
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Project Synopsis 
 
The aim of this study was to investigate macrophage interactions with electrospun 
scaffolds and quantify the expression of four vital angiogenic growth factors in vitro, 
vascular endothelial growth factor (VEGF), acidic fibroblast growth factor (aFGF), basic 
fibroblast growth factor (bFGF) and transforming growth factor beta-1 (TGF-β1).  This 
study will further help in evaluating the potential of these electrospun constructs as 
vascular grafts for tissue repair and regeneration in situ.  
Polydioxanone (PDO) and elastin were dissolved in 1,1,1,3,3,3-hexafluoro-2-
propanol  in concentrations of 100 mg/ml and 200 mg/ml respectively. These solutions 
were blended in the ratios of 50:50, 70:30 and 90:10 (PDO:elastin) by volume. Pure PDO 
(100:0) and pure elastin (0:100) were also used in the study. These were then electrospun 
into a flat sheet.  
Human peripheral blood monocytes (CRL9855, ATCC) were seeded into culture at 
a density of 6x107 cells per 75 cm2 flask in Dulbecco’s modified eagle medium (high 
glucose) with 20% heat inactivated fetal bovine serum and 10% heat inactivated AB+ 
serum. This cell concentration provided a high seeding density for differentiation of 
monocytes to macrophages. Macrophages were obtained after 21 days of culture. The 
macrophages were then seeded at a density of 400,000 cells/well on electrospun (10 mm) 
disks of PDO, elastin, PDO:elastin blends (50:50, 70:30 and 90:10) and on tissue culture 
plastic (TCP) in a 48 well plate. The supernatants were collected on day 7, 14, 21 and 28 
and stored at -70°C until analyzed by ELISA.
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BACKGROUND INFORMATION 
 
Blood Vessel Architecture 
 
The complex blood vessel system of the human body serves two main functions, 
delivery of oxygen and nutrients to the tissues and removal of metabolites for clearance or 
re-oxygenation. As shown in figure 1, the artery is composed of three different layers or 
tunics of different compositions which surround a hollow core or lumen through which the 
blood flows. The innermost layer, surrounding the lumen is known as the intima and is 
made up of single layer of endothelial cells on a basement membrane rich in collagen IV 
and elastin. This layer contacts the bloodstream and endothelial cells provide a crucial 
barrier to platelet activation by secreting specific molecules like nitric oxide and prevent 
thrombus formation. The thick middle layer, the media, is composed of several layers of 
smooth muscle cells in an extracellular matrix of collagen types I and III, elastin and 
proteoglycans. In elastic arteries like the aorta, the elastic lamellae allow the artery to 
maintain sufficient blood pressure with variations in hemodynamic stress of the cardiac 
systole and diastole. In muscular arteries, elastin is assembled as fibers. The outermost 
adventitial layer is composed of fibroblasts and randomly arranged collagen type I.  This, 
collagen provides tensile support and prevents vessel rupture. The proteoglycans contribute
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to the compressibility and the elastin fibers give elasticity to the vessel and provide the 
ability to recover from pulsatile deformations. Its elastic nature dominates the low strain
mechanical response of the vessel to blood flow and prevents pulsatile energy from being 
dissipated as heat [4, 5].  
 
 
Fig. 1. Blood vessel architecture [6]. 
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The Macrophage 
 
Macrophages belong to the mononuclear phagocyte system. This system comprises 
the bone marrow monoblasts, pro-monocytes, peripheral blood monocytes and tissue 
macrophages. They share a common progenitor cell with granulocytes in the bone marrow. 
This common progenitor is called the colony-forming unit, granulocyte-macrophage 
(CFU-GM) because of its ability to give rise to colonies of monocytes and neutrophils in a 
semi-solid marrow cultures. When monocytes enter the blood stream and migrate into 
tissues, they undergo final differentiation to tissue macrophages (Fig.2). Macrophages are 
present ubiquitously in all tissues and display great structural and functional heterogeneity 
as histiocytes, alveolar macrophages (lungs), kupffer cells (liver), osteoclasts (bone), 
peritoneal macrophages (peritoneum), synovia type A cells (synovium), or microglia 
(central nervous system). Macrophages are set into different functional states by a process 
known as activation. Activation of macrophages entails increased phagocytic or 
microbicidal activities and alteration of their chemotactic response and secretory activities. 
Activation is a complex process involving different stimuli. Macrophages increase 
performance of some functions and down regulate others. Some of the listed activators in 
literature are concanavalin A, endotoxin, lipopolysacchride and various cytokines such as 
interferon-γ (IFN- γ), granulocyte-macrophage colony stimulating factor (GM-CSF), 
platelet-activating factor (PAF) or monocyte chemotactic protein [7, 8].  
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Macrophages also secrete a repertoire of proteases and growth factors  such as bFGF, GM-
CSF,  transforming growth factor- alpha (TGF-α), TGF-β, Insulin-like growth factor-I 
(IGF-I), Platelet-derived growth factor (PDGF), VEGF, and other monokines such as 
inerleukins (IL-1, IL-6, IL-8), tumor necrosis factor-alpha (TNF- α), substance P, 
prostaglandins, interferons, thrombospondin 1 [7].  
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Fig. 2. The mononuclear-phagocyte system [9]. 
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Macrophages and Angiogenesis 
 
The macrophage is the major differentiated cell of the mononuclear phagocyte 
system. It originates in the bone marrow as an immature monocyte. After entering the 
peripheral blood, monocytes are recruited by chemokines into the tissue and undergo 
differentiation into macrophages. The specialization and activation of these cells are 
mainly influenced by local stimuli [10, 11]. Angiogenesis is a multi-step process involving 
various cell types. It is tightly regulated by several microenvironmental factors in the blood 
vessel, including soluble molecules (e.g., growth factors and cytokines), extracellular 
matrices (ECM), interactions between adjacent endothelial cells (ECs) and ECs with other 
cell types, as well as mechanical forces originating from ECs themselves, blood flow, and 
extravascular tissue activity (Fig.3). 
 
9 
 
 
 
Fig.3 Microenvironmental cues that affect angiogenesis [12]. 
 
The outstanding role of macrophages in angiogenesis can be attributed to their much 
longer half life as compared to granulocytes and platelets and secretion of myriad of 
growth factors for initiation, maintenance and termination of the angiogenic process 
(Fig.4). Also, macrophages are resident in all tissues in greater numbers than other blood 
borne cells and the distinct subtypes can always be recruited from the blood stream. They 
have heterogeneous functionality and can be activated from an inactive non-angiogenic 
stage to an angiogenic stage [7]. Growth factors are released by macrophages only when 
they are activated. The authors speculate that the macrophages will get activated when they 
come in contact with the biomaterials [13]. There are two known phenotypes of 
macrophage activation. Classically activated macrophages up regulate pro-inflammatory 
cytokines, inhibit anti-inflammatory cytokines and fibrogenesis. On the other hand, 
alternatively activated macrophages inhibit pro-inflammatory cytokines, promote anti-
inflammatory cytokines and enhance fibrogenesis. The biomaterial adherent macrophage 
phenotype is known to have a different cytokine profile than either classically or 
alternatively activated macrophages indicating that the biomaterial activation is unique. 
Macrophage activation and cytokine expression can be modulated by the material 
properties, such as surface chemistry and surface topography [14]. 
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Fig. 4. Role of macrophages in angiogenesis. 
 
 
 
 
 
 
 
Vital Angiogenic Molecules 
 
 
The molecule VEGF (previously known as Vascular Permeability Factor) is by far 
the most potent angiogenic growth factor known. It is secreted in biologically active form 
by activated peripheral blood monocytes/macrophages. Besides directly stimulating 
angiogenesis, it also helps in regulating the production of proteases and their inhibitors, 
and promotes endothelial cell proliferation, migration, differentiation and survival [1]. 
VEGF induces vascular dilation and exudation of fibrin. The deposition of fibrin induces 
monocyte migration, penetration and tunnel formation in this new ECM [12].  bFGF and 
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aFGF belong to a family of heparin binding (fibroblast) growth factors and can promote 
almost every phase of the angiogenesis cascade. They both induce urokinase-type 
plasminogen activator (uPA) in different cell types [3] . Secreted uPA converts 
plasminogen into plasmin, a protease which degrades ECM proteins and activates other 
metalloproteinases (MMPs) necessary for further degradation and remodeling of ECM . It 
also stimulates proliferation, DNA synthesis and migration of endothelial cells towards the 
place where new blood supply is needed [3] . Unlike VEGF, the actions of bFGF and 
aFGF are not limited to ECs. They act on most cells derived from mesoderm and ectoderm 
such as fibroblasts, pericytes and ECs. 
TGF-β1 has both stimulatory and inhibitory effects on angiogenesis. It stimulates in 
vivo angiogenesis in presence of inflammatory response but is an inhibitor of endothelial 
cell growth in vitro [12, 15]. Actions of TGF-β1 depend upon its concentration and ECM 
organization. Higher concentration and two dimensional culture systems inhibited the 
migration and proliferation of endothelial cells whereas low concentration and three 
dimensional culture systems supported the proliferation and tube formation of endothelial 
cells [7]. It was also found that TGF-β1 mediates the inhibition of endothelial cell 
proliferation upon endothelial cell-pericyte contact in a coculture system. These effects are 
critical in stabilizing nascent, immature blood vessels [12]. Over expression of this 
cytokine results in fibrotic conditions since it promotes accumulation of ECM molecules 
[15].  
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Tissue macrophages also express Angiopoietin-1 (Ang-1). It binds to the Tie-2 
receptor and potently induces network formation, chemotactic response and survival 
during apoptosis. It also stabilizes nascent vessels by tightening the interaction between 
endothelial and periendothelial cells. It also causes sprouting of endothelial cells in fibrin 
gel but does not stimulate proliferation. As an antagonist of Ang-1, Angiopoietin-2 (Ang-
2) competes with Ang-1 for binding of Tie-2 and blocks vessel stabilization from Tie-2 
signaling. It thus loosens the interactions of ECs with pericytes and the ECM leading to 
vessel destabilization. Many different cell types, including ECs, fibroblasts, macrophages 
and platelets release a molecule called platelet-derived growth factor (PDGF). In blood 
vessel walls, PDGF receptors can be found in smooth muscle cells (SMCs), ECs and 
pericytes. In vivo studies have demonstrated that proliferation and migration of pericytes 
along angiogenic sprouts is mediated by PDGF [12]. 
 
Biomaterials for Vascular Tissue Engineering 
 
The ideal vascular prosthetic must have the following performance characteristics: 
ease of handling, suture retention, ease of suture replacement, flexibility with kink 
resistance, biocompatibility, durability after implanatation and association with 
surrounding connective tissue, compliance matching that of the native artery, and 
resistance to aneurysm formation. Also, the graft must be easily manufactured, 
economical, easily stored and available in a variety of sizes [16].   
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Initial graft research focused on Poly(ehtylene terephthalate) (Dacron) and 
expanded poly(tetrafluoroethylene) (e-PTFE) as prosthetic vascular grafts. Both Dacron 
and e-PTFE react with blood components and perigraft tissues in both advantageous and 
injurious ways. It has been documented that monocytes and macrophages produce 
cytokines such as interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor 
alpha (TNF-α) when incubated with Dacron and e-PTFE [17].  
However, these prostheses remained permanently within the host after implantation. The 
concept of a slowly absorbable graft that could stimulate rapid and controlled regenerative 
process producing a “neoartery” was first described by Wesolowski et al. [18] and 
Ruderman et al. [19]. These grafts were partially bioresorbable and composed of Dacron 
and polylactide yarns. Bowland et al. described the use of Vicryl (a copolymer of 
polyglycolide and polylactide) as a fully bioresorbable vascular graft [20]. These early 
grafts were susceptible to aneurismal rupture and dilation.  
Greisler et al. evaluated woven poly(glycolic acid) (PGA) grafts in a rabbit model. 
Four weeks after implantation, these grafts were shown to contain an inner capsule 
composed of a confluent layer of endothelial cells and smooth muscle like myofibroblasts 
in the midst of dense collagen fibers. Similarly constructed and implanted Dacron grafts 
failed to show the results described above [21, 22]. 
It is also important for the bioresorbable graft to regenerate a complex tissue of 
sufficient strength before prosthetic degradation so as to minimize the risk of aneurismal 
dilation. To circumvent this problem two or more bioresorbable materials with different 
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resorption rates can be combined so that the more rapidly absorbed material induces rapid 
tissue ingrowth while the second material provides structural support [23]. Such composite 
grafts containing 69% polyglactin 910 (PG910) and 31% polypropylene were implanted 
into rabbit and dog arteries [24]. These grafts demonstrated 100% 1-year patency with no 
aneurysms. In another study, composite grafts of 74% PG910 and 26% polydioxanone 
(PDO/PDS) also showed 100% patency with no aneurysms one year after implantation 
[25]. PDO is a colorless, crystalline, biodegradable polymer that was developed for wound 
closure sutures. It exhibits high flexibility, higher strength retention, slower absorption 
rate, and lower inflammatory response as compared to poly(glycolide lactide) and 
poly(glycolic acid) [16].  Greisler et al. published results utilizing PDO absorbable 
vascular prosthetics in a rabbit aortic model of regeneration. The results showed no 
perigraft hematomas and the myofibroblast migration paralleled the macrophage–mediated 
degradation of the PDO structure. A confluent EC lining was present within two weeks, 
with the compliance of the explants at 1 year resembling an artery [26]. In another study, 
Geisler et al. demonstrated that PDO grafts had the highest production ratio of PGI2/TxA2 
at a seven fold increase versus PGA and approximately equal to the native aorta control. 
The study showed a tissue dependence response in terms of thrombogenicity and the grafts 
containing PDO were less thrombogenic [27]. 
Recent advances in tissue engineering have shifted focus on synthetic and natural 
blends of polymers for use as vascular grafts. The introduction of natural polymer 
increases the hydrophilicity and cellular affinity of the material. This in turn enhances the 
15 
 
 
 
cell attachment, migration and proliferation. The natural polymer invariably degrades first, 
creating more space for cell migration and tissue regeneration while the synthetic polymer 
maintains the structural integrity. Zhang et al. created gelatin and PCL electrospun blends 
that exhibited enhanced mechanical properties and better wettability than that obtained 
from PCL or gelatin alone [28]. A mixture of heparin and poly (ethylene glycol) (PEG) 
was electrospun for potential use as a wound dressing. The presence of PEG slowed down 
the release of heparin and permitted better biological outcomes [29]. Boland et al. 
demonstrated the electrospinning of a blend of collagen and elastin for use as vascular 
tissue engineered constructs [30]. 
In elastic tissues, polymers of elastin confer elasticity to the vessel and provide the 
ability to recover from pulsatile deformations [30]. Elastin is an abundant protein 
component of the native arterial tissue and is chosen to confer elasticity and bioactivity to 
the vascular prosthetic [5].  In arteries, elastin dictates tissue mechanics at low strains 
before stiffer collagen fibers are engaged. Elastin also prevents dynamic tissue creep by 
stretching under load and recoiling to their original configurations after the load is 
released. It is also a strong autocrine regulator of vascular smooth cells activity and this is 
crucial for prevention of fibrocellular pathology. Elastin induces actin stress fiber 
organization, inhibits smooth muscle cell proliferation, and regulates migration via a non-
integrin heterotrimeric G protein coupled signaling pathway. In the absence of extracellular 
elastin, smooth muscle cell proliferation stenoses arteries. Therefore, in order to ensure 
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proper mechanical function of the vessel and to prevent vessel stenosis, tissue engineered 
vascular implants must include an elastic component [6].  
In the field of vascular tissue engineering and vascular prosthetic it is important to 
match or mimic the mechanical properties of the native tissue to eliminate mismatches 
between the prosthetic and the native tissue. Previous studies conducted on PDO: elastin 
blends have shown a range of mechanical properties that included those of native arterial 
tissue. The mechanical properties of the 50:50 blend closely matched the range of femoral 
artery values in almost every instance, the only exception being that the electrospun 50:50 
blend exhibited higher ultimate stresses than the native vessel. Compliance is another 
important property of the blood vessels that assists in pushing blood through the circulation 
and prevents flow stagnation and graft thrombosis. It was found that the grafts containing 
elastin had greater compliance than pure PDO grafts [5].  
The biomaterials chosen for this study were PDO blended with elastin in three 
ratios (50:50, 70:30, 90:10) to create nanofibrous, seamless tubular constructs for potential 
use as acellular vascular prosthetics [5]. This study will further help in evaluating the 
capability of this vascular prosthetic to promote in situ arterial tissue regeneration. To 
evaluate the effect of fiber diameter on macrophage interactions with biomaterials, 
different concentration of PDO (60, 80, 100, 120, 140mg/ml) were also electrospun and 
tested.  The process used for the fabrication of this construct is electrospinning. Briefly, it 
consists of a charged polymer solution separated from an oppositely charged target by a set 
distance (air gap) to create a static electric field. When the electrostatic forces within the 
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solution overcome the surface tension of the solution, a fine jet of entangled polymer 
chains is drawn out. The solvent evaporates as the jet travels through the air gap, and a dry 
fiber is collected on the target. The translation/rotation of the target ensures uniformity in 
structural characteristics [5]. 
The growth factors are released by macrophages only when they are activated. The 
authors speculate that the macrophages will be activated when they come in contact with 
the biomaterials. Macrophage activation through stimulation by lipopolysaccharide (LPS) 
or concanavalin A has been done in previous studies. It has been observed that the 
presence of such agents not only proportionately increase all the growth factor levels, but 
also manipulate the types being expressed leading to misinterpretation of the data. 
Therefore, in these studies we refrained from using stimulating agents to assess the growth 
factor production [31]. 
 
Host Response to Biomaterials 
 
Following tissue injury, the normal healing response is initiated through a series of 
intricate events that include acute inflammation, the formation of granulation tissue, and 
eventual scar formation. The immediate response is to deluge the injured area with blood. 
Cleavage of fibrinogen within the blood into fibrin is done to form a blood clot that 
promotes platelet adhesion and aggregation. A spectrum of cytokines and growth factors 
are released to recruit white blood cells, primarily neutrophils. Monocytes are then 
18 
 
 
 
recruited to the wound site where they differentiate into macrophages. The macrophages 
are responsible for cleaning up the wound site, by phagocytosis of debris which may 
include foreign material, bacteria, necrotic and apoptotic cells. In addition, they are also 
required for recruiting cells such as fibroblasts and endothelial cells. These cells convert 
the fibrin clot into a highly vascularized granulation tissue. The formation of blood vessels 
is crucial to the healing wound. Fibroblasts subsequently replace the granulation tissue by 
an extracellular matrix (ECM). The degree of ECM remodeling is dependant on the extent 
and location of the injury. It has been observed that in some cases, complete restoration of 
the tissue architecture is possible but mostly granulation tissue is remodeled into scar 
tissue.  
 
When a biomaterial is implanted into the body it induces a different response, 
termed the foreign body reaction (Fig.5 and 6). Briefly, a biomaterial elicits nonspecific 
protein adsorption immediately upon implantation. Many different proteins adsorb to the 
surface in a range of conformations from native to denatured. However, non-specific 
protein adsorption has never been observed in the normal physiological process of wound 
healing. Thus, nonspecific protein adsorption is believed to be an instigator in the foreign 
body reaction. A variety of cells, that are key players in normal wound healing (such as 
monocytes, leukocytes, and platelets) adhere to these biomaterial surfaces and as a result 
may lead to upregulation of cytokines and subsequent proinflammatory mechanisms.  
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Macrophage response to biomaterials is dependent on the size of the materials. 
Material particle sizes smaller than a single-nucleated macrophage (normally around 10 
µm in diameter) can be phagocytozed by macrophages. Large particles (between 10 µm 
and several hundred micrometres) that are beyond the capacity of macrophage 
phagocytosis may be engulfed by multinucleated giant cells or foreign body giant cells [2]. 
Since the implant is significantly larger than the adhered macrophages, it prevents them 
from phagocytosing the foreign body. This initiates the chronic inflammation at the 
biomaterial interface and is followed by the fusion of the frustrated macrophages to form 
multinucleated foreign body giant cells that often persist for the lifetime of the implant.  
The resolution of macrophage responses to biomaterials depends on whether the material is 
degradable or nondegradable. Degradable materials are usually degraded by phagocytosis, 
or eroded via extracellular resorption, with or without the involvement of foreign body 
giant cells. Any associated inflammation is taken care of after total resorption of the 
biodegradable materials. Nondegradable materials cannot be degraded either within the 
macrophage phagosome, or by extracellular resorption. Macrophages infiltrate constantly 
to phagocytoze undigested particles or to fuse into foreign body giant cells and persist on 
the surface of the implanted materials. Therefore, for non-degradable biomaterials, it is 
vital to choose those that cause less macrophage responses for long-term implantation. 
In the final stage of the foreign body reaction, the device is covered by an 
avascular, collagenous fibrous tissue that is usually 50–200 µm thick [32, 33]. 
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Fig. 5. Diagram showing macrophage response to biomaterials [2]. 
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Fig. 6. Foreign body reaction to an implanted synthetic biomaterial [33]. 
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Electrospinning 
 
A number of processing techniques such as drawing, template synthesis, phase 
separation, self assembly and electrospinning  have been utilized to synthesize polymer 
nanofibers for tissue engineering. Drawing is a process that can make one-by-one very 
long single nanofibers. However, only a viscoelastic material that can undergo very strong 
deformations can be made into nanofibers through drawing. Template synthesis, uses a 
nanoporous membrane as a template to make nanofibers of a solid or hollow shape. A 
major drawback of the method is the inability to synthesize one-by-one continuous 
nanofibers. The phase separation method consists of dissolution, gelation, extraction using 
a different solvent, followed by freezing and drying. In self assembly procedure, pre-
existing, individual components organize themselves into desired patterns and functions. 
However, both phase separation and self assembly processes are very time consuming in 
processing continuous polymer nanofibers. Electrospinning is an advantageous processing 
method for synthesizing one-by-one continuous nanofibers from various different 
polymers [34]. It’s also a very simple, straight forward, cost-effective method to generate 
different types of scaffolds. Briefly, it consists of a charged polymer solution separated 
from an oppositely charged target by a set distance (air gap) to create a static electric field 
(Fig.7). When the electrostatic forces within the solution overcome the surface tension of 
the solution, a fine jet of entangled polymer chains is drawn out. The solvent evaporates as 
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the jet travels through the air gap, and a dry fiber is collected on the target. The 
translation/rotation of the target ensures uniformity in structural characteristics [5] .  
There are great advantages of using electrospinning for tissue engineering applications. 
Electrospinning is capable of producing extremely thin fibers with diameters ranging from 
microns down to few nanometers. In native tissues, cells are typically about one to two 
orders of magnitude bigger than the structural ECM proteins (50-300 nm). This allows the 
cells to be in direct contact with many ECM fibers. Therefore, the small-size fibers mimic 
the structural dimension of the ECM of several native tissues which are deposited and 
characterized by well-organized hierarchical fibrous structures realigning from nanometer 
to millimeter scale. The scaffolds produced by electrospinning possess a highly porous 
microstructure with interconnected pores and extremely high surface-area-to-volume ratio, 
which is conducive to tissue growth. In addition, it is a very versatile technique and allows 
the use of a variety of polymers, blends of different polymers, and inorganic materials. 
Recent advances in electrospinning have shown that integration of various substances such 
as additives, biomolecules, and living cells is possible in scaffolds for tailoring different 
application requirements [28].  
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Fig. 7. Schematic of the Electrospinning process [16].  
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Materials and Methods 
 
 
 
Electrospinning 
 
 
PDO (Ethicon Inc.) and soluble elastin (Elastin Products Co., Inc) were dissolved 
in 1,1,1,3,3,3-hexafluoro-2-propanol (TCI America) in concentrations of 100 mg/ml and 
200 mg/ml respectively. These solutions were blended in the ratios of 50:50, 70:30 and 
90:10 (PDO:elastin) by volume. Pure PDO (100:0) and pure elastin (0:100) were also used 
in the study. In addition PDO was also dissolved in the concentrations of 60, 80, 100, 120 
and 140 mg/ml. These solutions were then loaded into a Becton Dickinson syringe (5.0 ml) 
with an 18 gauge blunt tip needle and placed in a KD scientific syringe pump to be 
dispensed at a rate of 4-6 ml/hr (higher flow rates were used for high PDO ratio blends). 
Solutions were then electrospun onto a flat rotating stainless steel mandrel (2.5 cm wide x 
10.2 cm long x 0.3 cm thick) to produce a flat sheet. All electrospinning was performed at 
an applied voltage of 22kV, while the mandrel was rotated at a rate of 500 rpm and placed 
12 cm away from the needle tip [5]. 
 
 Cross Linking  
 
 
Soluble elastin being a natural polymer lacks substantial strength upon hydration. 
Therefore, all elastin rich electrospun scaffolds were crosslinked using a method developed 
by Barnes et al. [35] . Briefly, the scaffolds were soaked for 18 hours in 167 mM (50 fold 
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molar excess for 200 mg/ml of elastin) of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC, Sigma Aldrich) solution in ethanol, followed by a 2 hour rinse in 0.1 
M sodium phosphate. PDO and 90:10 blend did not require crosslinking, but were 
processed the same way in order to exclude any variability in the results.  
 
Permeability Measurement 
 
 
Circular discs were punched out of the scaffolds using a 10 mm biopsy punch and 
the permeability was individually measured using the simple flowmeter described in [36]. 
Briefly, the amount of time for a known volume of water to flow through a bound area of 
the scaffold was recorded and calculations were done using equation 1. 
                                   Permeability = Q                                                                (1) 
                                                           Aht 
 
Where Q is the volume of water passed through the scaffold (ml) in time t (min) and A and 
h are the area (cm2) and the thickness (cm) of the scaffold respectively. The distance 
between the water source (horizontal 10 mL pipette) and the scaffold was maintained at a 
level to produce a pressure head of 120 mm Hg (Fig.8). 
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Fig. 8. Diagram of the permeability measurement device used in the study [36]. 
 
Cell Culture 
 
 
Human peripheral blood monocytes (CRL-9855, ATCC) were seeded into culture 
at a density of 6x107 cells per 75 cm2 flask in Dulbecco’s modified eagle medium (high 
glucose) with 20% heat inactivated fetal bovine serum and 10% heat inactivated AB+ 
serum. This cell concentration provided a high seeding density for differentiation of 
monocytes to macrophages. Macrophages were obtained after 21 days of culture. It has 
been documented that serum proteins found in Human AB+ Serum (e.g. Human 
Immunoglobulin (IgG)) promote maturation by interacting with monocytes via Fc 
receptors [37]. Monocytes also show macrophage characteristics such as increased 
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cytolysis and intracellular levels of lysosomal enzymes in the presence of autologous 
serum [38]. Godiska et al. reported that the chemoattractant macrophage derived 
chemokine (MDC) has a very specific pattern of expression and is highly expressed by 
macrophages and monocyte-derived dendritic cells, but is not expressed by freshly isolated 
monocytes, granulocytic cells, or natural killer cells [39]. Macrophages were then adapted 
for culture in Macrophage-SFM (serum free media) (Invitrogen). A sequential adaptation 
technique was used to adapt the cells as a drastic change from 30% serum to a serum free 
media would have been too stressful for the cells. The ratio of serum supplemented media 
(SSM) to serum free media (SFM) was gradually reduced every week. For the first week 
cells were cultured in 80:20 (SSM:SFM). In the following week the ratio of media used 
was 50:50 and then a gradual increase in the amount of SFM media was made as the cells 
were cultured in 20:80, followed by 0:100. No changes in morphology or viability were 
observed after the adaptation. Monocytes and macrophages were cultured at a density of 
50,000 cells/well in a 12 well plate and the supernatants were collected and stored at day 7, 
14, 21 and 28 until needed for the MDC expression analysis. 
 
 
 Cell Seeding on Scaffolds 
 
 
Macrophages were adapted for culture in serum free media (Invitrogen). A serum 
free medium formulation was chosen to exclude the contribution of serum derived 
angiogenesis factors in the study. Conventional tissue culture techniques that frequently 
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employ serum stimulate cells by various biological modifiers such as hormones, proteins 
and other biomolecules. 
Prior to cell seeding the scaffolds were disinfected by soaking in ethanol for 10 min 
followed by repeated rinses in phosphate buffered saline (PBS). The macrophages were 
then seeded at a density of 400,000 cells/well on electrospun (10 mm) disks of PDO (60 to 
140 mg/ml), elastin, PDO:elastin blends (50:50, 70:30 and 90:10) and on tissue culture 
plastic (TCP) in a 48 well plate. The supernatants were collected on day 7, 14, 21 and 28 
and stored at -70°C until needed. One disc of each ratio was also removed at the above 
mentioned time points, fixed in 10% formalin and processed for histology (Hematoxylin 
and Eosin staining; H&E).  
 
Enzyme Linked Immunosorbent Assay (ELISA) 
 
 
The growth factor expression was quantified using Enzyme Linked Immunosorbent 
Assay (ELISA). The cell culture supernatants were thawed and each ELISA for specific 
growth factors (VEGF, aFGF, bFGF, TGF-β1) to be evaluated was carried out using 
construction kits (Antigenix America) as per manufacturer’s instructions. The standard 
curve was generated using log-log fit (Soft MaxPro 4.8) and its linear part was used to 
determine the concentration of the factor in the supernatant. Latent TGF-β1 was activated 
to its immuno-reactive form using the procedure outlined in the kit’s instructions. 
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Statistical Analysis 
 
All statistical analysis of the data was based on a Kruskal-Wallis one way analysis 
of variance on ranks and a Tukey-Kramer pairwise multiple comparison procedure 
(α=0.05) performed with JMP® IN 7 statistical software (SAS Institute). 
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Results and Discussion 
 
 Permeability Measurement 
 
 
Statistically, PDO was significantly more permeable than the rest of the materials 
and 90:10 was more permeable than 70:30 and 50:50 (Fig.9). Therefore, cell infiltration 
can be directly related to the permeability of the scaffold. It can be concluded that PDO 
and the 90:10 blend have high porosities as pore size is directly proportional to the 
permeability and the fiber diameter of the electrospun scaffolds. Sanders et al. reported 
reduced macrophage density on small diameter fibers (<6 µm) attributed to a reduced cell 
material contact surface area [40]. The permeability test results for the different 
concentrations of the PDO scaffold showed that 100 mg/ml and 120 mg/ml scaffolds 
were statistically significantly different from the 60 mg/ml and 80 mg/ml scaffolds. Also, 
the permeability within each of these two groups was not significantly different from one 
another. However, the 140 mg/ml scaffold was not statistically different from the 60 
mg/ml and 80 mg/ml scaffolds.  
It has been documented that pore size of PDO scaffolds increases linearly with 
concentration. The reason why the permeability peaks at about 120 mg/ml and falls 
dramatically for 140 mg/ml scaffold could be attributed to the pore collapse of these 
structures. It could have been that the pores and fibers were so large that the pores 
actually collapsed under the water pressure and the void spaces were filled with fibers 
since the entire scaffold is dynamic and can move around on a micron scale level 
(Fig.10).
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Fig. 9. Permeability measurements for samples of electrospun PDO:elastin scaffolds. 
Error bars indicate standard error of the mean. 
 
 
 
 
 
 
 
Fig. 10. Permeability measurements for samples of electrospun PDO scaffolds of varying 
concentration. Error bars indicate standard error of the mean. 
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Macrophage Derived Chemokine ELISA 
 
 
In order to confirm the maturation of monocytes to macrophages a Macrophage 
Derived Chemokine (MDC) (R&D Systems) ELISA was performed. This was based on 
the fact that macrophages produce MDC constitutively while monocytes release it only 
upon stimulation [39]. Significant statistical differences were found on day 21 of culture 
(Fig.11). Statistical differences were not observed on the other days. However, it was 
seen that both monocytes and macrophages were producing comparable amounts of 
MDC. This can be explained by taking into account the fact that a mixed cell population 
was purchased from ATCC. In addition, it has been documented that after 7 days of 
culture in serum free media monocytes transform into macrophages [1]. In another 
example, human peripheral blood monocytes cultured in 10% autologous serum were 
shown to have differentiated to macrophages after 5-6 days [41, 42]. They also reported 
that the number of adherent cells were similar when grown in the presence of AB serum 
or autologous serum [42]. The MDC expression was also found to be consistent from day 
7 to 28, however it is unclear what the baseline measurements (day 0) would reveal. 
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Fig. 11. Quantification of MDC production by macrophages and monocytes. Error bars 
indicate standard error of the mean. 
 
 
 Macrophage Factor Secretion (Quantification by ELISA) 
 
 
The growth factor expression analysis revealed that macrophages released high 
amounts of VEGF and aFGF with a steady increase from day 7 to 28. The expression of 
TGF-β1 was relatively low. The production of bFGF was below the detectable level (10 
pg/ml) of the kit. The activation of macrophages in this case is theorized to be integrin 
mediated. Integrins are a large family of cell surface receptors that mediate cell-
extracellular matrix and intracellular interactions. Enough information is not available to 
provide insight into how activation may occur when cells encounter engineered materials 
composed of proteins and synthetic polymers.  
As shown in figure 12, the expression of VEGF on biomaterial adherent 
macrophages did not vary considerably among the different scaffolds. The secretion of 
aFGF and VEGF was found to remain largely independent of the scaffold material. The 
production of both aFGF and VEGF showed a steady increase from day 7 to 28. VEGF 
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secretion on day 28 was found to be statistically higher than day 7 on all materials. The 
secretion of aFGF on day 28 was found to be higher than both day 7 and 14 on all 
materials. This indicates that the production of both aFGF and VEGF was found to be 
significantly higher in later stages of cell culture. 
The expression of TGF-β1 gradually decreased from day 7 to 21 and came back 
up again on day 28. The only exceptions to this trend were the PDO and the 70:30 
scaffold. Statistically significant differences were found in TGF-β1 secretion between 
PDO and PDO:elastin (90:10) blend on day 7. Macrophages secrete TGF-β1 as well as its 
binding protein. The binding protein inhibits the interaction of TGF-β1 with its cell 
surface receptor, thus showing that TGF-β1-binding protein complex is biologically 
inactive. This interaction modulates the expression and action of TGF-β1. 
Figure 13 shows the growth factor expression on PDO scaffolds of varying 
concentrations. It was observed that the growth factor secretion was significantly higher 
on high PDO concentration scaffolds. The only exception to this trend was the secretion 
of TGF- β1 and aFGF on the 80 mg/ml scaffold which was significantly higher than the 
140 mg/ml scaffold on day 21. Similar results were obtained again in the expression of 
TGF-β1 as its concentration went progressively low from day 7 to 21 and came back up 
again on day 28. The only exception to this trend was the 100 mg/ml PDO scaffold. 60 
mg/ml scaffold showed a rather constant level of TGF-β1 production from day 7 to 28. 
VEGF secretion was found to be largely material independent. It was also found that 
VEGF production was significantly higher on day 28 as compared to day 7 on all 
concentrations of PDO. A detailed statistical report is provided in the appendix for other 
statistical differences not reported in the text. 
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It was observed that the growth factor secretion on scaffolds was comparable to 
the growth factor secretion on tissue culture plastic. This shows that the materials are 
neither elevating nor suppressing the secretory function of macrophages. It can be 
anticipated that these materials as vascular implants will support natural tissue 
regeneration process with minimum risk of tumors or undesirable inflammatory 
reactions. Too much of growth factor secretion can lead to uncontrolled cell migration 
and proliferation. There are reports of ‘leaky’ blood vessels which exhibit fibrosis, 
oedema, inflammation and haemorrhagic ulcers due to over expression of VEGF and 
TGF-β1 [15, 43].  
The degradation activity of macrophages was observed to be higher on scaffolds 
containing high ratios of PDO. This can be attributed to the high permeability of these 
materials, which enabled good infiltration of macrophages throughout the entire thickness 
of the scaffold. Permeability is directly related to the pore size and the fiber diameter. It is 
known that increase in fiber size is associated with an increase in pore size. Drastic pH 
changes were observed in the cell culture media on various samples. Low pH was 
generated in the microenvironment of the scaffolds containing high PDO ratios, 
indicating that they are undergoing degradation. Previous studies have shown that low pH 
stimulates macrophages to release growth factors [44].  
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Fig. 12. Quantification of macrophage secretory activity on PDO:elastin scaffolds using 
ELISA. Error bars indicate standard error of the mean. Symbols ‘*’ and ‘ø’ indicate a 
statistically significant difference from the control groups, media and TCP respectively 
(p<0.05). 
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Fig. 13. Quantification of macrophage secretory activity on PDO scaffolds of varying 
concentrations using ELISA. Error bars indicate standard error of the mean. Symbols ‘*’ 
and ‘ø’ indicate a statistically significant difference from the control groups, media and 
TCP respectively (p<0.05). 
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Histology 
 
 
Histology revealed greater cell infiltration into the fibrous networks of the PDO 
and 90:10 scaffolds (Fig.14). The cells migrated to some extent on the elastin scaffold 
and remained on the surface of the 50:50 and the 70:30 blend. It has been documented 
that when angiogenesis occurs in a remodeling situation such as a bioresorbable vascular 
prosthetic, it is accompanied by an inflammatory infiltration composed of monocytes and 
macrophages. The abolishment of this infiltration dramatically reduces the angiogenesis 
and wound healing response [45]. Also, it has been reported that the number of 
macrophages directly correlate to the degree of angiogenesis [46, 47]. To evaluate the 
effect of porosity on the infiltration of macrophages in the scaffold, PDO scaffolds were 
electrospun in the range of 60 mg/ml to 140 mg/ml. The increasing concentration 
correlates to the increasing fiber diameter and pore size. It has been documented that the 
diameter of PDO fibers increased linearly from 0.18 to 1.4µm range as the solution 
concentration increased in the range 42-167 mg/ml. The pore size however exhibited a 
non-linear relation with solution concentration. It was found to increase from 0.5 µm2 to 
24.5 µm2 as solution concentration increased from 42 to 167 mg/ml. The statistical 
analysis indicated that the 42–56 mg/ml pore areas were significantly different from the 
71–167 mg/ml pore areas, though the pore areas within each of those groups were not 
significantly different from each other. Porosity and surface area are two key variables 
influencing interaction of structures with the host environment. For example, a highly 
porous structure with a large surface area may be more favorable to cell attachment and 
infiltration of cellular components [16]. The current study is in agreement with this fact. 
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As shown in Figure 15, the macrophages did not migrate at all into the fibrous networks 
of 60 mg/ml and 80 mg/ml PDO scaffolds. They largely remained on the surface and did 
not migrate through even at day 21 of culture. On the other hand, scaffolds spun at 
concentrations of 100 mg/ml, 120 mg/ml and 140 mg/ml showed increased cell migration 
and infiltration throughout the entire thickness of the scaffold. Thus, it can be concluded 
that the macrophages did not infiltrate elastin and 50:50 scaffolds due to the highly 
compact and dense structure of these scaffolds which led to low pore size.  
 
 
 
Fig. 14. Histology (H&E) performed at day 21(20x magnification). 
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Fig. 15. Histology performed on various concentrations of PDO at day 21  
(40x magnification). 
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Conclusion 
 
 
 
Biomaterials upon implantation acquire a layer of host proteins prior to interacting with 
host cells. The type, concentration and conformations of these surface adsorbed proteins 
are dependent on the material surface properties [14]. Macrophage adhesion to the 
material surface adherent protein layer is integrin mediated. It provides intracellular 
signals that dictate macrophage behavior. A cascade of events are triggered that affect 
cytoskeletal rearrangements and formation of adhesion structures. Macrophages undergo 
cytoskeletal remodeling to spread over the material surface. When cells are properly 
adhered to the cell surface, integrin signaling mediates survival. Disruption of the 
adhesion signals lead to anoikis (term for apoptosis induced by cell detachment from its 
supportive matrix) [14]. The adherent macrophages become activated in order to 
phagocytose the biomaterial. This is followed by cytokine secretion that directs the 
inflammatory and wound healing response to the biomaterial. In vitro testing of growth 
factor profiles released by adherent macrophages can be an initial means of assaying 
biocompatibility [14]. 
The study provides an angiogenic assessment of macrophage implant interaction 
by quantifying the growth factor secretion in the cell culture supernatants. It was 
observed that the growth factor secretion profiles for VEGF and aFGF attained similar 
levels around day 21 and 28 for all materials. Previous studies have shown that 
macrophages do not produce bFGF on biomaterials unless they are stimulated by 
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concanavalin A or lipopolysaccharide [1]. The fact that bFGF expression is strong in 
chronic inflammations and weak in healthy tissue is also known. It has also been 
established in that bFGF is not absolutely mandatory for angiogenesis and that 
vascularization does occur in its absence [12]. 
Elastin incorporation into the scaffolds was done to improve the in vitro 
bioactivity of the matrix and also to improve the mechanical properties of the material 
[5]. The study however shows better results on scaffolds with high PDO ratios as 
compared to the elastin rich scaffolds. The increased cell migration and proliferation on 
PDO and the 90:10 blend can be largely attributed to the high porosities of these 
materials. Therefore, it can be concluded that scaffolds with high PDO ratios were more 
conducive to tissue regeneration and angiogenesis with minimum risk of thrombosis.  
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APPENDIX A: Statistical Analysis 
 
 
 
Oneway Analysis of Day 7 By PDO:elastin scaffolds for VEGF secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD PDO 90:10 70:30 50:50 TCP ELASTIN media 
PDO -4.0523 -2.4293 -2.1203 -1.8493 -1.5883 -0.3780 -0.4572 
90:10 -2.4293 -4.0523 -3.7433 -3.4723 -3.2113 -2.0010 -2.0802 
70:30 -2.1203 -3.7433 -4.0523 -3.7813 -3.5203 -2.3100 -2.3892 
50:50 -1.8493 -3.4723 -3.7813 -4.0523 -3.7913 -2.5810 -2.6602 
TCP -1.5883 -3.2113 -3.5203 -3.7913 -4.0523 -2.8420 -2.9212 
ELASTIN -0.3780 -2.0010 -2.3100 -2.5810 -2.8420 -4.0523 -4.1316 
media -0.4572 -2.0802 -2.3892 -2.6602 -2.9212 -4.1316 -7.0189 
 
Positive values show pairs of means that are significantly different. 
 
 
Level  Mean 
PDO A 6.0166667 
90:10 A 4.3936667 
70:30 A 4.0846667 
50:50 A 3.8136667 
TCP A 3.5526667 
ELASTIN A 2.3423333 
media A 0.7430000 
 
Levels not connected by same letter are significantly different. 
 
 
Level  - Level Difference Lower CL Upper CL Difference 
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Level  - Level Difference Lower CL Upper CL Difference 
PDO media 5.273667 -0.45722 11.00455  
PDO ELASTIN 3.674333 -0.37801 7.72668  
90:10 media 3.650667 -2.08022 9.38155  
70:30 media 3.341667 -2.38922 9.07255  
50:50 media 3.070667 -2.66022 8.80155  
TCP media 2.809667 -2.92122 8.54055  
PDO TCP 2.464000 -1.58835 6.51635  
PDO 50:50 2.203000 -1.84935 6.25535  
90:10 ELASTIN 2.051333 -2.00101 6.10368  
PDO 70:30 1.932000 -2.12035 5.98435  
70:30 ELASTIN 1.742333 -2.31001 5.79468  
PDO 90:10 1.623000 -2.42935 5.67535  
ELASTIN media 1.599333 -4.13155 7.33022  
50:50 ELASTIN 1.471333 -2.58101 5.52368  
TCP ELASTIN 1.210333 -2.84201 5.26268  
90:10 TCP 0.841000 -3.21135 4.89335  
90:10 50:50 0.580000 -3.47235 4.63235  
70:30 TCP 0.532000 -3.52035 4.58435  
90:10 70:30 0.309000 -3.74335 4.36135  
70:30 50:50 0.271000 -3.78135 4.32335  
50:50 TCP 0.261000 -3.79135 4.31335  
 
Oneway Analysis of Day 14 By PDO:elastin scaffolds for VEGF secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD ELASTIN 70:30 90:10 TCP 50:50 PDO media 
ELASTIN -1.7627 -1.7277 -1.3520 -1.0160 1.8230 3.5176 3.0188 
70:30 -1.7277 -1.7627 -1.3870 -1.0510 1.7880 3.4826 2.9838 
90:10 -1.3520 -1.3870 -1.7627 -1.4267 1.4123 3.1070 2.6081 
TCP -1.0160 -1.0510 -1.4267 -1.7627 1.0763 2.7710 2.2721 
50:50 1.8230 1.7880 1.4123 1.0763 -1.7627 -0.0680 -0.5669 
PDO 3.5176 3.4826 3.1070 2.7710 -0.0680 -1.7627 -2.2615 
media 3.0188 2.9838 2.6081 2.2721 -0.5669 -2.2615 -3.0531 
 
Positive values show pairs of means that are significantly different. 
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Level   Mean 
ELASTIN A   6.2546667 
70:30 A   6.2196667 
90:10 A   5.8440000 
TCP A   5.5080000 
50:50   B 2.6690000 
PDO   B 0.9743333 
media   B 0.7430000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
ELASTIN media 5.511667 3.01882 8.004518  
70:30 media 5.476667 2.98382 7.969518  
ELASTIN PDO 5.280333 3.51762 7.043045  
70:30 PDO 5.245333 3.48262 7.008045  
90:10 media 5.101000 2.60815 7.593851  
90:10 PDO 4.869667 3.10695 6.632379  
TCP media 4.765000 2.27215 7.257851  
TCP PDO 4.533667 2.77095 6.296379  
ELASTIN 50:50 3.585667 1.82295 5.348379  
70:30 50:50 3.550667 1.78795 5.313379  
90:10 50:50 3.175000 1.41229 4.937712  
TCP 50:50 2.839000 1.07629 4.601712  
50:50 media 1.926000 -0.56685 4.418851  
50:50 PDO 1.694667 -0.06805 3.457379  
ELASTIN TCP 0.746667 -1.01605 2.509379  
70:30 TCP 0.711667 -1.05105 2.474379  
ELASTIN 90:10 0.410667 -1.35205 2.173379  
70:30 90:10 0.375667 -1.38705 2.138379  
90:10 TCP 0.336000 -1.42671 2.098712  
PDO media 0.231333 -2.26152 2.724185  
ELASTIN 70:30 0.035000 -1.72771 1.797712  
 
Oneway Analysis of Day 21 By PDO:elastin scaffolds for VEGF secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
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Abs(Dif)-LSD 90:10 70:30 50:50 PDO TCP ELASTIN media 
90:10 -3.4694 -3.4548 -3.1484 -3.0844 -1.7768 -1.2854 2.4512 
70:30 -3.4548 -3.4694 -3.1631 -3.0991 -1.7914 -1.3001 2.4365 
50:50 -3.1484 -3.1631 -3.4694 -3.4054 -2.0978 -1.6064 2.1302 
PDO -3.0844 -3.0991 -3.4054 -3.4694 -2.1618 -1.6704 2.0662 
TCP -1.7768 -1.7914 -2.0978 -2.1618 -3.4694 -2.9781 0.7585 
ELASTIN -1.2854 -1.3001 -1.6064 -1.6704 -2.9781 -3.4694 0.2672 
media 2.4512 2.4365 2.1302 2.0662 0.7585 0.2672 -6.0092 
 
Positive values show pairs of means that are significantly different. 
 
 
Level   Mean 
90:10 A   8.1006667 
70:30 A   8.0860000 
50:50 A   7.7796667 
PDO A   7.7156667 
TCP A   6.4080000 
ELASTIN A   5.9166667 
media   B 0.7430000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
90:10 media 7.357667 2.45115 12.26418  
70:30 media 7.343000 2.43649 12.24951  
50:50 media 7.036667 2.13015 11.94318  
PDO media 6.972667 2.06615 11.87918  
TCP media 5.665000 0.75849 10.57151  
ELASTIN media 5.173667 0.26715 10.08018  
90:10 ELASTIN 2.184000 -1.28543 5.65343  
70:30 ELASTIN 2.169333 -1.30010 5.63876  
50:50 ELASTIN 1.863000 -1.60643 5.33243  
PDO ELASTIN 1.799000 -1.67043 5.26843  
90:10 TCP 1.692667 -1.77676 5.16210  
70:30 TCP 1.678000 -1.79143 5.14743  
50:50 TCP 1.371667 -2.09776 4.84110  
PDO TCP 1.307667 -2.16176 4.77710  
TCP ELASTIN 0.491333 -2.97810 3.96076  
90:10 PDO 0.385000 -3.08443 3.85443  
70:30 PDO 0.370333 -3.09910 3.83976  
90:10 50:50 0.321000 -3.14843 3.79043  
70:30 50:50 0.306333 -3.16310 3.77576  
50:50 PDO 0.064000 -3.40543 3.53343  
90:10 70:30 0.014667 -3.45476 3.48410  
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Oneway Analysis of Day 28 By PDO:elastin scaffolds for VEGF secretion 
 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD 70:30 50:50 90:10 PDO ELASTIN TCP media 
70:30 -2.1492 -2.1306 -1.3342 -0.8182 -0.3496 -0.2162 5.3965 
50:50 -2.1306 -2.1492 -1.3529 -0.8369 -0.3682 -0.2349 5.3779 
90:10 -1.3342 -1.3529 -2.1492 -1.6332 -1.1646 -1.0312 4.5815 
PDO -0.8182 -0.8369 -1.6332 -2.1492 -1.6806 -1.5472 4.0655 
ELASTIN -0.3496 -0.3682 -1.1646 -1.6806 -2.1492 -2.0159 3.5969 
TCP -0.2162 -0.2349 -1.0312 -1.5472 -2.0159 -2.1492 3.4635 
media 5.3965 5.3779 4.5815 4.0655 3.5969 3.4635 -3.7226 
 
Positive values show pairs of means that are significantly different. 
 
 
Level   Mean 
70:30 A   9.1790000 
50:50 A   9.1603333 
90:10 A   8.3640000 
PDO A   7.8480000 
ELASTIN A   7.3793333 
TCP A   7.2460000 
media   B 0.7430000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
70:30 media 8.436000 5.39654 11.47546  
50:50 media 8.417333 5.37788 11.45679  
90:10 media 7.621000 4.58154 10.66046  
PDO media 7.105000 4.06554 10.14446  
ELASTIN media 6.636333 3.59688 9.67579  
TCP media 6.503000 3.46354 9.54246  
70:30 TCP 1.933000 -0.21622 4.08222  
50:50 TCP 1.914333 -0.23489 4.06355  
70:30 ELASTIN 1.799667 -0.34955 3.94889  
50:50 ELASTIN 1.781000 -0.36822 3.93022  
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Level  - Level Difference Lower CL Upper CL Difference 
70:30 PDO 1.331000 -0.81822 3.48022  
50:50 PDO 1.312333 -0.83689 3.46155  
90:10 TCP 1.118000 -1.03122 3.26722  
90:10 ELASTIN 0.984667 -1.16455 3.13389  
70:30 90:10 0.815000 -1.33422 2.96422  
50:50 90:10 0.796333 -1.35289 2.94555  
PDO TCP 0.602000 -1.54722 2.75122  
90:10 PDO 0.516000 -1.63322 2.66522  
PDO ELASTIN 0.468667 -1.68055 2.61789  
ELASTIN TCP 0.133333 -2.01589 2.28255  
70:30 50:50 0.018667 -2.13055 2.16789  
 
 
 
 
 
 
 
 
 
 
Fit Y by X Group 
Oneway Analysis of Day 7 By PDO:elastin scaffolds for aFGF secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD media PDO ELASTIN 50:50 90:10 TCP 70:30 
media -0.8157 0.6320 0.6953 0.8730 0.9147 0.9567 1.0207 
PDO 0.6320 -0.4709 -0.4076 -0.2299 -0.1883 -0.1463 -0.0823 
ELASTIN 0.6953 -0.4076 -0.4709 -0.2933 -0.2516 -0.2096 -0.1456 
50:50 0.8730 -0.2299 -0.2933 -0.4709 -0.4293 -0.3873 -0.3233 
90:10 0.9147 -0.1883 -0.2516 -0.4293 -0.4709 -0.4289 -0.3649 
TCP 0.9567 -0.1463 -0.2096 -0.3873 -0.4289 -0.4709 -0.4069 
70:30 1.0207 -0.0823 -0.1456 -0.3233 -0.3649 -0.4069 -0.4709 
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Positive values show pairs of means that are significantly different. 
 
 
Level   Mean 
media A   2.1610000 
PDO   B 0.8630000 
ELASTIN   B 0.7996667 
50:50   B 0.6220000 
90:10   B 0.5803333 
TCP   B 0.5383333 
70:30   B 0.4743333 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
media 70:30 1.686667 1.02067 2.352660  
media TCP 1.622667 0.95667 2.288660  
media 90:10 1.580667 0.91467 2.246660  
media 50:50 1.539000 0.87301 2.204994  
media ELASTIN 1.361333 0.69534 2.027327  
media PDO 1.298000 0.63201 1.963994  
PDO 70:30 0.388667 -0.08226 0.859595  
ELASTIN 70:30 0.325333 -0.14560 0.796262  
PDO TCP 0.324667 -0.14626 0.795595  
PDO 90:10 0.282667 -0.18826 0.753595  
ELASTIN TCP 0.261333 -0.20960 0.732262  
PDO 50:50 0.241000 -0.22993 0.711929  
ELASTIN 90:10 0.219333 -0.25160 0.690262  
ELASTIN 50:50 0.177667 -0.29326 0.648595  
50:50 70:30 0.147667 -0.32326 0.618595  
90:10 70:30 0.106000 -0.36493 0.576929  
50:50 TCP 0.083667 -0.38726 0.554595  
TCP 70:30 0.064000 -0.40693 0.534929  
PDO ELASTIN 0.063333 -0.40760 0.534262  
90:10 TCP 0.042000 -0.42893 0.512929  
50:50 90:10 0.041667 -0.42926 0.512595  
 
Oneway Analysis of Day 14 By PDO:elastin scaffolds for aFGF secretion 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
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Abs(Dif)-LSD media PDO 70:30 TCP ELASTIN 50:50 90:10 
media -0.73603 0.18304 0.62104 0.62304 0.70670 0.78970 0.79037 
PDO 0.18304 -0.42495 0.01305 0.01505 0.09872 0.18172 0.18239 
70:30 0.62104 0.01305 -0.42495 -0.42295 -0.33928 -0.25628 -0.25561 
TCP 0.62304 0.01505 -0.42295 -0.42495 -0.34128 -0.25828 -0.25761 
ELASTIN 0.70670 0.09872 -0.33928 -0.34128 -0.42495 -0.34195 -0.34128 
50:50 0.78970 0.18172 -0.25628 -0.25828 -0.34195 -0.42495 -0.42428 
90:10 0.79037 0.18239 -0.25561 -0.25761 -0.34128 -0.42428 -0.42495 
 
Positive values show pairs of means that are significantly different. 
 
 
Level    Mean 
media A     2.1610000 
PDO   B   1.3770000 
70:30     C 0.9390000 
TCP     C 0.9370000 
ELASTIN     C 0.8533333 
50:50     C 0.7703333 
90:10     C 0.7696667 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
media 90:10 1.391333 0.790369 1.992298  
media 50:50 1.390667 0.789702 1.991631  
media ELASTIN 1.307667 0.706702 1.908631  
media TCP 1.224000 0.623036 1.824964  
media 70:30 1.222000 0.621036 1.822964  
media PDO 0.784000 0.183036 1.384964  
PDO 90:10 0.607333 0.182387 1.032279  
PDO 50:50 0.606667 0.181721 1.031613  
PDO ELASTIN 0.523667 0.098721 0.948613  
PDO TCP 0.440000 0.015054 0.864946  
PDO 70:30 0.438000 0.013054 0.862946  
70:30 90:10 0.169333 -0.255613 0.594279  
70:30 50:50 0.168667 -0.256279 0.593613  
TCP 90:10 0.167333 -0.257613 0.592279  
TCP 50:50 0.166667 -0.258279 0.591613  
70:30 ELASTIN 0.085667 -0.339279 0.510613  
ELASTIN 90:10 0.083667 -0.341279 0.508613  
TCP ELASTIN 0.083667 -0.341279 0.508613  
ELASTIN 50:50 0.083000 -0.341946 0.507946  
70:30 TCP 0.002000 -0.422946 0.426946  
50:50 90:10 0.000667 -0.424279 0.425613  
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Oneway Analysis of Day 21 By PDO:elastin scaffolds for aFGF secretion 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD PDO media ELASTIN TCP 90:10 70:30 50:50 
PDO -3.2311 -3.2912 -1.7745 -1.6965 -1.2975 -1.2505 -1.1391 
media -3.2912 -5.5965 -4.3912 -4.3132 -3.9142 -3.8672 -3.7559 
ELASTIN -1.7745 -4.3912 -3.2311 -3.1531 -2.7541 -2.7071 -2.5958 
TCP -1.6965 -4.3132 -3.1531 -3.2311 -2.8321 -2.7851 -2.6738 
90:10 -1.2975 -3.9142 -2.7541 -2.8321 -3.2311 -3.1841 -3.0728 
70:30 -1.2505 -3.8672 -2.7071 -2.7851 -3.1841 -3.2311 -3.1198 
50:50 -1.1391 -3.7559 -2.5958 -2.6738 -3.0728 -3.1198 -3.2311 
 
Positive values show pairs of means that are significantly different. 
 
 
Level  Mean 
PDO A 3.4393333 
media A 2.1610000 
ELASTIN A 1.9826667 
TCP A 1.9046667 
90:10 A 1.5056667 
70:30 A 1.4586667 
50:50 A 1.3473333 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
PDO 50:50 2.092000 -1.13914 5.323138  
PDO 70:30 1.980667 -1.25047 5.211804  
PDO 90:10 1.933667 -1.29747 5.164804  
PDO TCP 1.534667 -1.69647 4.765804  
PDO ELASTIN 1.456667 -1.77447 4.687804  
PDO media 1.278333 -3.29119 5.847852  
media 50:50 0.813667 -3.75585 5.383186  
media 70:30 0.702333 -3.86719 5.271852  
media 90:10 0.655333 -3.91419 5.224852  
ELASTIN 50:50 0.635333 -2.59580 3.866471  
TCP 50:50 0.557333 -2.67380 3.788471  
ELASTIN 70:30 0.524000 -2.70714 3.755138  
59 
 
 
Level  - Level Difference Lower CL Upper CL Difference 
ELASTIN 90:10 0.477000 -2.75414 3.708138  
TCP 70:30 0.446000 -2.78514 3.677138  
TCP 90:10 0.399000 -2.83214 3.630138  
media TCP 0.256333 -4.31319 4.825852  
media ELASTIN 0.178333 -4.39119 4.747852  
90:10 50:50 0.158333 -3.07280 3.389471  
70:30 50:50 0.111333 -3.11980 3.342471  
ELASTIN TCP 0.078000 -3.15314 3.309138  
90:10 70:30 0.047000 -3.18414 3.278138  
 
Oneway Analysis of Day 28 By PDO:elastin scaffolds for aFGF secretion 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD PDO 70:30 50:50 ELASTIN 90:10 media TCP 
PDO -3.4183 -0.7043 -0.3963 -0.3937 -0.3523 -1.5612 0.0503 
70:30 -0.7043 -3.4183 -3.1103 -3.1077 -3.0663 -4.2752 -2.6637 
50:50 -0.3963 -3.1103 -3.4183 -3.4157 -3.3743 -4.5832 -2.9717 
ELASTIN -0.3937 -3.1077 -3.4157 -3.4183 -3.3770 -4.5859 -2.9743 
90:10 -0.3523 -3.0663 -3.3743 -3.3770 -3.4183 -4.6272 -3.0157 
media -1.5612 -4.2752 -4.5832 -4.5859 -4.6272 -5.9207 -4.6386 
TCP 0.0503 -2.6637 -2.9717 -2.9743 -3.0157 -4.6386 -3.4183 
 
Positive values show pairs of means that are significantly different. 
 
 
Level   Mean 
PDO A   5.4340000 
70:30 A B 2.7200000 
50:50 A B 2.4120000 
ELASTIN A B 2.4093333 
90:10 A B 2.3680000 
media A B 2.1610000 
TCP   B 1.9653333 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
PDO TCP 3.468667 0.05034 6.886989  
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Level  - Level Difference Lower CL Upper CL Difference 
PDO media 3.273000 -1.56124 8.107237  
PDO 90:10 3.066000 -0.35232 6.484322  
PDO ELASTIN 3.024667 -0.39366 6.442989  
PDO 50:50 3.022000 -0.39632 6.440322  
PDO 70:30 2.714000 -0.70432 6.132322  
70:30 TCP 0.754667 -2.66366 4.172989  
70:30 media 0.559000 -4.27524 5.393237  
50:50 TCP 0.446667 -2.97166 3.864989  
ELASTIN TCP 0.444000 -2.97432 3.862322  
90:10 TCP 0.402667 -3.01566 3.820989  
70:30 90:10 0.352000 -3.06632 3.770322  
70:30 ELASTIN 0.310667 -3.10766 3.728989  
70:30 50:50 0.308000 -3.11032 3.726322  
50:50 media 0.251000 -4.58324 5.085237  
ELASTIN media 0.248333 -4.58590 5.082570  
90:10 media 0.207000 -4.62724 5.041237  
media TCP 0.195667 -4.63857 5.029904  
50:50 90:10 0.044000 -3.37432 3.462322  
ELASTIN 90:10 0.041333 -3.37699 3.459655  
50:50 ELASTIN 0.002667 -3.41566 3.420989  
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Fit Y by X Group 
 
Oneway Analysis of day 7 by PDO:Elastin scaffolds for TGF-β1 secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.55539 0.05 
 
Abs(Dif)-LSD p90:el10 cells p50:el50 el p70:el30 pdo media 
p90:el10 -128.50 -90.95 -43.96 -41.38 -56.04 10.35 -11.09 
cells -90.95 -128.50 -81.52 -78.93 -93.60 -27.21 -48.65 
p50:el50 -43.96 -81.52 -128.50 -125.92 -140.58 -74.20 -95.64 
el -41.38 -78.93 -125.92 -128.50 -143.17 -76.78 -98.22 
p70:el30 -56.04 -93.60 -140.58 -143.17 -157.38 -92.45 -109.75 
pdo 10.35 -27.21 -74.20 -76.78 -92.45 -128.50 -149.94 
media -11.09 -48.65 -95.64 -98.22 -109.75 -149.94 -222.58 
 
Positive values show pairs of means that are significantly different. 
 
 
Level   Mean 
p90:el10 A   178.93900 
cells A B 141.38333 
p50:el50 A B 94.39567 
el A B 91.81267 
p70:el30 A B 91.30700 
pdo   B 40.08867 
media A B 8.30000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
p90:el10 media 170.6390 -11.093 352.3715  
p90:el10 pdo 138.8503 10.346 267.3546  
cells media 133.0833 -48.649 314.8158  
cells pdo 101.2947 -27.210 229.7989  
p90:el10 p70:el30 87.6320 -56.040 231.3041  
p90:el10 el 87.1263 -41.378 215.6306  
p50:el50 media 86.0957 -95.637 267.8281  
p90:el10 p50:el50 84.5433 -43.961 213.0476  
el media 83.5127 -98.220 265.2451  
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Level  - Level Difference Lower CL Upper CL Difference 
p70:el30 media 83.0070 -109.749 275.7634  
p50:el50 pdo 54.3070 -74.197 182.8113  
el pdo 51.7240 -76.780 180.2283  
p70:el30 pdo 51.2183 -92.454 194.8905  
cells p70:el30 50.0763 -93.596 193.7485  
cells el 49.5707 -78.934 178.0749  
cells p50:el50 46.9877 -81.517 175.4919  
p90:el10 cells 37.5557 -90.949 166.0599  
pdo media 31.7887 -149.944 213.5211  
p50:el50 p70:el30 3.0887 -140.583 146.7608  
p50:el50 el 2.5830 -125.921 131.0873  
el p70:el30 0.5057 -143.166 144.1778  
 
Oneway Analysis of day 14 by PDO:elastin scaffolds for TGF-β1 secretion 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.45353 0.05 
 
Abs(Dif)-LSD p90:el10 p70:el30 el pdo p50:el50 cells media 
p90:el10 -127.98 -84.32 -34.58 -30.44 -21.80 -22.36 -48.56 
p70:el30 -84.32 -127.98 -78.24 -74.10 -65.46 -66.02 -92.22 
el -34.58 -78.24 -127.98 -123.84 -115.19 -115.76 -141.96 
pdo -30.44 -74.10 -123.84 -127.98 -119.33 -119.90 -146.10 
p50:el50 -21.80 -65.46 -115.19 -119.33 -110.83 -112.01 -140.73 
cells -22.36 -66.02 -115.76 -119.90 -112.01 -127.98 -154.18 
media -48.56 -92.22 -141.96 -146.10 -140.73 -154.18 -221.67 
 
Positive values show pairs of means that are significantly different. 
 
 
Level  Mean 
p90:el10 A 140.72967 
p70:el30 A 97.06933 
el A 47.33267 
pdo A 43.19333 
p50:el50 A 42.81275 
cells A 35.11067 
media A 8.30000 
 
Levels not connected by same letter are significantly different. 
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Level  - Level Difference Lower CL Upper CL Difference 
p90:el10 media 132.4297 -48.561 313.4203  
p90:el10 cells 105.6190 -22.361 233.5987  
p90:el10 p50:el50 97.9169 -21.797 217.6310  
p90:el10 pdo 97.5363 -30.443 225.5160  
p90:el10 el 93.3970 -34.583 221.3767  
p70:el30 media 88.7693 -92.221 269.7600  
p70:el30 cells 61.9587 -66.021 189.9384  
p70:el30 p50:el50 54.2566 -65.457 173.9706  
p70:el30 pdo 53.8760 -74.104 181.8557  
p70:el30 el 49.7367 -78.243 177.7164  
p90:el10 p70:el30 43.6603 -84.319 171.6400  
el media 39.0327 -141.958 220.0233  
pdo media 34.8933 -146.097 215.8840  
p50:el50 media 34.5128 -140.731 209.7562  
cells media 26.8107 -154.180 207.8013  
el cells 12.2220 -115.758 140.2017  
pdo cells 8.0827 -119.897 136.0624  
p50:el50 cells 7.7021 -112.012 127.4161  
el p50:el50 4.5199 -115.194 124.2340  
el pdo 4.1393 -123.840 132.1190  
pdo p50:el50 0.3806 -119.333 120.0946  
 
Oneway Analysis of day 21 by PDO:elastin scaffolds for TGF-β1 secretion 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.55539 0.05 
 
Abs(Dif)-LSD pdo p90:el10 p70:el30 p50:el50 cells el media 
pdo -197.56 -93.88 -87.19 -58.69 -77.98 -41.48 -113.78 
p90:el10 -93.88 -197.56 -190.87 -162.37 -181.67 -145.16 -217.47 
p70:el30 -87.19 -190.87 -197.56 -169.06 -188.36 -151.85 -224.16 
p50:el50 -58.69 -162.37 -169.06 -197.56 -216.86 -180.35 -252.66 
cells -77.98 -181.67 -188.36 -216.86 -241.96 -207.69 -273.63 
el -41.48 -145.16 -151.85 -180.35 -207.69 -197.56 -269.87 
media -113.78 -217.47 -224.16 -252.66 -273.63 -269.87 -342.19 
 
Positive values show pairs of means that are significantly different. 
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Level  Mean 
pdo A 173.91267 
p90:el10 A 70.22733 
p70:el30 A 63.53767 
p50:el50 A 35.03833 
cells A 31.01650 
el A 17.82833 
media A 8.30000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
pdo media 165.6127 -113.781 445.0062  
pdo el 156.0843 -41.477 353.6454  
pdo cells 142.8962 -77.984 363.7761  
pdo p50:el50 138.8743 -58.687 336.4354  
pdo p70:el30 110.3750 -87.186 307.9360  
pdo p90:el10 103.6853 -93.876 301.2464  
p90:el10 media 61.9273 -217.466 341.3208  
p70:el30 media 55.2377 -224.156 334.6312  
p90:el10 el 52.3990 -145.162 249.9600  
p70:el30 el 45.7093 -151.852 243.2704  
p90:el10 cells 39.2108 -181.669 260.0908  
p90:el10 p50:el50 35.1890 -162.372 232.7500  
p70:el30 cells 32.5212 -188.359 253.4011  
p70:el30 p50:el50 28.4993 -169.062 226.0604  
p50:el50 media 26.7383 -252.655 306.1318  
cells media 22.7165 -273.625 319.0581  
p50:el50 el 17.2100 -180.351 214.7710  
cells el 13.1882 -207.692 234.0681  
el media 9.5283 -269.865 288.9218  
p90:el10 p70:el30 6.6897 -190.871 204.2507  
p50:el50 cells 4.0218 -216.858 224.9018  
 
Oneway Analysis of day 28 By PDO:elastin scaffolds for TGF-β1 secretion 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.70826 0.05 
 
Abs(Dif)-LSD p50:el50 pdo p90:el10 el p70:el30 cells media 
p50:el50 -149.00 -120.67 -90.68 -71.89 -57.03 -48.92 -48.87 
pdo -120.67 -149.00 -119.01 -100.23 -85.36 -77.25 -77.20 
p90:el10 -90.68 -119.01 -149.00 -130.22 -115.35 -107.24 -107.19 
el -71.89 -100.23 -130.22 -121.66 -106.80 -98.69 -102.55 
p70:el30 -57.03 -85.36 -115.35 -106.80 -121.66 -113.55 -117.42 
cells -48.92 -77.25 -107.24 -98.69 -113.55 -121.66 -125.53 
media -48.87 -77.20 -107.19 -102.55 -117.42 -125.53 -210.72 
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Positive values show pairs of means that are significantly different. 
 
 
Level  Mean 
p50:el50 A 141.92300 
pdo A 113.59200 
p90:el10 A 83.60000 
el A 77.79867 
p70:el30 A 62.93600 
cells A 54.82500 
media A 8.30000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
p50:el50 media 133.6230 -48.866 316.1116  
pdo media 105.2920 -77.197 287.7806  
p50:el50 cells 87.0980 -48.921 223.1169  
p50:el50 p70:el30 78.9870 -57.032 215.0059  
p90:el10 media 75.3000 -107.189 257.7886  
el media 69.4987 -102.553 241.5505  
p50:el50 el 64.1243 -71.895 200.1433  
pdo cells 58.7670 -77.252 194.7859  
p50:el50 p90:el10 58.3230 -90.678 207.3243  
p70:el30 media 54.6360 -117.416 226.6879  
pdo p70:el30 50.6560 -85.363 186.6749  
cells media 46.5250 -125.527 218.5769  
pdo el 35.7933 -100.226 171.8123  
pdo p90:el10 29.9920 -119.009 178.9933  
p90:el10 cells 28.7750 -107.244 164.7939  
p50:el50 pdo 28.3310 -120.670 177.3323  
el cells 22.9737 -98.685 144.6327  
p90:el10 p70:el30 20.6640 -115.355 156.6829  
el p70:el30 14.8627 -106.796 136.5217  
p70:el30 cells 8.1110 -113.548 129.7700  
p90:el10 el 5.8013 -130.218 141.8203  
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Fit Y by X Group 
Oneway Analysis of Day 7 by PDO scaffolds of varying concentration for VEGF secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD 140 mg/ml 100 mg/ml 60 mg/ml 80 mg/ml 120 mg/ml TCP Media 
140 mg/ml -0.2537 -0.1633 -0.0127 -0.0080 0.0290 0.1313 1.0149 
100 mg/ml -0.1633 -0.2537 -0.1030 -0.0983 -0.0613 0.0410 0.9246 
60 mg/ml -0.0127 -0.1030 -0.2537 -0.2490 -0.2120 -0.1097 0.7739 
80 mg/ml -0.0080 -0.0983 -0.2490 -0.2537 -0.2167 -0.1143 0.7692 
120 mg/ml 0.0290 -0.0613 -0.2120 -0.2167 -0.2537 -0.1513 0.7322 
TCP 0.1313 0.0410 -0.1097 -0.1143 -0.1513 -0.2537 0.6299 
Media 1.0149 0.9246 0.7739 0.7692 0.7322 0.6299 -0.4394 
 
Positive values show pairs of means that are significantly different. 
 
 
Level     Mean 
140 mg/ml A       1.4336667 
100 mg/ml A B     1.3433333 
60 mg/ml A B C   1.1926667 
80 mg/ml A B C   1.1880000 
120 mg/ml   B C   1.1510000 
TCP     C   1.0486667 
Media       D 0.0600000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
140 mg/ml Media 1.373667 1.01491 1.732425  
100 mg/ml Media 1.283333 0.92457 1.642092  
60 mg/ml Media 1.132667 0.77391 1.491425  
80 mg/ml Media 1.128000 0.76924 1.486759  
120 mg/ml Media 1.091000 0.73224 1.449759  
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Level  - Level Difference Lower CL Upper CL Difference 
TCP Media 0.988667 0.62991 1.347425  
140 mg/ml TCP 0.385000 0.13132 0.638681  
100 mg/ml TCP 0.294667 0.04099 0.548347  
140 mg/ml 120 mg/ml 0.282667 0.02899 0.536347  
140 mg/ml 80 mg/ml 0.245667 -0.00801 0.499347  
140 mg/ml 60 mg/ml 0.241000 -0.01268 0.494681  
100 mg/ml 120 mg/ml 0.192333 -0.06135 0.446014  
100 mg/ml 80 mg/ml 0.155333 -0.09835 0.409014  
100 mg/ml 60 mg/ml 0.150667 -0.10301 0.404347  
60 mg/ml TCP 0.144000 -0.10968 0.397681  
80 mg/ml TCP 0.139333 -0.11435 0.393014  
120 mg/ml TCP 0.102333 -0.15135 0.356014  
140 mg/ml 100 mg/ml 0.090333 -0.16335 0.344014  
60 mg/ml 120 mg/ml 0.041667 -0.21201 0.295347  
80 mg/ml 120 mg/ml 0.037000 -0.21668 0.290681  
60 mg/ml 80 mg/ml 0.004667 -0.24901 0.258347  
 
Oneway Analysis of Day 14 by PDO scaffolds of varying concentration for VEGF secretion 
 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD 100 mg/ml TCP 80 mg/ml 140 mg/ml 120 mg/ml 60 mg/ml Media 
100 mg/ml -0.3592 -0.3205 -0.2038 -0.1745 -0.1332 -0.0175 1.7144 
TCP -0.3205 -0.3592 -0.2425 -0.2132 -0.1718 -0.0562 1.6757 
80 mg/ml -0.2038 -0.2425 -0.3592 -0.3298 -0.2885 -0.1728 1.5590 
140 mg/ml -0.1745 -0.2132 -0.3298 -0.3592 -0.3178 -0.2022 1.5297 
120 mg/ml -0.1332 -0.1718 -0.2885 -0.3178 -0.3592 -0.2435 1.4884 
60 mg/ml -0.0175 -0.0562 -0.1728 -0.2022 -0.2435 -0.3592 1.3727 
Media 1.7144 1.6757 1.5590 1.5297 1.4884 1.3727 -0.6221 
 
Positive values show pairs of means that are significantly different. 
 
 
Level   Mean 
100 mg/ml A   2.2823333 
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Level   Mean 
TCP A   2.2436667 
80 mg/ml A   2.1270000 
140 mg/ml A   2.0976667 
120 mg/ml A   2.0563333 
60 mg/ml A   1.9406667 
Media   B 0.0600000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
100 mg/ml Media 2.222333 1.71438 2.730290  
TCP Media 2.183667 1.67571 2.691623  
80 mg/ml Media 2.067000 1.55904 2.574956  
140 mg/ml Media 2.037667 1.52971 2.545623  
120 mg/ml Media 1.996333 1.48838 2.504290  
60 mg/ml Media 1.880667 1.37271 2.388623  
100 mg/ml 60 mg/ml 0.341667 -0.01751 0.700846  
TCP 60 mg/ml 0.303000 -0.05618 0.662179  
100 mg/ml 120 mg/ml 0.226000 -0.13318 0.585179  
TCP 120 mg/ml 0.187333 -0.17185 0.546513  
80 mg/ml 60 mg/ml 0.186333 -0.17285 0.545513  
100 mg/ml 140 mg/ml 0.184667 -0.17451 0.543846  
140 mg/ml 60 mg/ml 0.157000 -0.20218 0.516179  
100 mg/ml 80 mg/ml 0.155333 -0.20385 0.514513  
TCP 140 mg/ml 0.146000 -0.21318 0.505179  
TCP 80 mg/ml 0.116667 -0.24251 0.475846  
120 mg/ml 60 mg/ml 0.115667 -0.24351 0.474846  
80 mg/ml 120 mg/ml 0.070667 -0.28851 0.429846  
140 mg/ml 120 mg/ml 0.041333 -0.31785 0.400513  
100 mg/ml TCP 0.038667 -0.32051 0.397846  
80 mg/ml 140 mg/ml 0.029333 -0.32985 0.388513  
 
Oneway Analysis of Day 21 by PDO scaffolds of varying concentration for VEGF secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
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Abs(Dif)-LSD 60 mg/ml TCP 80 mg/ml 100 mg/ml 120 mg/ml 140 mg/ml Media 
60 mg/ml -0.7145 -0.5218 -0.4635 -0.4088 -0.3732 -0.3678 1.6796 
TCP -0.5218 -0.7145 -0.6562 -0.6015 -0.5658 -0.5605 1.4869 
80 mg/ml -0.4635 -0.6562 -0.7145 -0.6598 -0.6242 -0.6188 1.4286 
100 mg/ml -0.4088 -0.6015 -0.6598 -0.7145 -0.6788 -0.6735 1.3739 
120 mg/ml -0.3732 -0.5658 -0.6242 -0.6788 -0.7145 -0.7092 1.3382 
140 mg/ml -0.3678 -0.5605 -0.6188 -0.6735 -0.7092 -0.7145 1.3329 
Media 1.6796 1.4869 1.4286 1.3739 1.3382 1.3329 -1.2375 
 
Positive values show pairs of means that are significantly different. 
 
 
Level   Mean 
60 mg/ml A   2.7500000 
TCP A   2.5573333 
80 mg/ml A   2.4990000 
100 mg/ml A   2.4443333 
120 mg/ml A   2.4086667 
140 mg/ml A   2.4033333 
Media   B 0.0600000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
60 mg/ml Media 2.690000 1.67955 3.700449  
TCP Media 2.497333 1.48688 3.507783  
80 mg/ml Media 2.439000 1.42855 3.449449  
100 mg/ml Media 2.384333 1.37388 3.394783  
120 mg/ml Media 2.348667 1.33822 3.359116  
140 mg/ml Media 2.343333 1.33288 3.353783  
60 mg/ml 140 mg/ml 0.346667 -0.36783 1.061162  
60 mg/ml 120 mg/ml 0.341333 -0.37316 1.055829  
60 mg/ml 100 mg/ml 0.305667 -0.40883 1.020162  
60 mg/ml 80 mg/ml 0.251000 -0.46350 0.965496  
60 mg/ml TCP 0.192667 -0.52183 0.907162  
TCP 140 mg/ml 0.154000 -0.56050 0.868496  
TCP 120 mg/ml 0.148667 -0.56583 0.863162  
TCP 100 mg/ml 0.113000 -0.60150 0.827496  
80 mg/ml 140 mg/ml 0.095667 -0.61883 0.810162  
80 mg/ml 120 mg/ml 0.090333 -0.62416 0.804829  
TCP 80 mg/ml 0.058333 -0.65616 0.772829  
80 mg/ml 100 mg/ml 0.054667 -0.65983 0.769162  
100 mg/ml 140 mg/ml 0.041000 -0.67350 0.755496  
100 mg/ml 120 mg/ml 0.035667 -0.67883 0.750162  
120 mg/ml 140 mg/ml 0.005333 -0.70916 0.719829  
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Oneway Analysis of Day 28 by PDO scaffolds of varying concentration for VEGF secretion 
 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD TCP 140 mg/ml 100 mg/ml 60 mg/ml 120 mg/ml 80 mg/ml Media 
TCP -0.5027 -0.1447 -0.1207 -0.0687 -0.0370 0.0443 2.0511 
140 mg/ml -0.1447 -0.5027 -0.4787 -0.4267 -0.3950 -0.3137 1.6931 
100 mg/ml -0.1207 -0.4787 -0.5027 -0.4507 -0.4190 -0.3377 1.6691 
60 mg/ml -0.0687 -0.4267 -0.4507 -0.5027 -0.4710 -0.3897 1.6171 
120 mg/ml -0.0370 -0.3950 -0.4190 -0.4710 -0.5027 -0.4213 1.5854 
80 mg/ml 0.0443 -0.3137 -0.3377 -0.3897 -0.4213 -0.5027 1.5041 
Media 2.0511 1.6931 1.6691 1.6171 1.5854 1.5041 -0.8707 
 
Positive values show pairs of means that are significantly different. 
 
 
Level    Mean 
TCP A     2.8220000 
140 mg/ml A B   2.4640000 
100 mg/ml A B   2.4400000 
60 mg/ml A B   2.3880000 
120 mg/ml A B   2.3563333 
80 mg/ml   B   2.2750000 
Media     C 0.0600000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
TCP Media 2.762000 2.05110 3.472895  
140 mg/ml Media 2.404000 1.69310 3.114895  
100 mg/ml Media 2.380000 1.66910 3.090895  
60 mg/ml Media 2.328000 1.61710 3.038895  
120 mg/ml Media 2.296333 1.58544 3.007229  
80 mg/ml Media 2.215000 1.50410 2.925895  
TCP 80 mg/ml 0.547000 0.04432 1.049679  
TCP 120 mg/ml 0.465667 -0.03701 0.968346  
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Level  - Level Difference Lower CL Upper CL Difference 
TCP 60 mg/ml 0.434000 -0.06868 0.936679  
TCP 100 mg/ml 0.382000 -0.12068 0.884679  
TCP 140 mg/ml 0.358000 -0.14468 0.860679  
140 mg/ml 80 mg/ml 0.189000 -0.31368 0.691679  
100 mg/ml 80 mg/ml 0.165000 -0.33768 0.667679  
60 mg/ml 80 mg/ml 0.113000 -0.38968 0.615679  
140 mg/ml 120 mg/ml 0.107667 -0.39501 0.610346  
100 mg/ml 120 mg/ml 0.083667 -0.41901 0.586346  
120 mg/ml 80 mg/ml 0.081333 -0.42135 0.584012  
140 mg/ml 60 mg/ml 0.076000 -0.42668 0.578679  
100 mg/ml 60 mg/ml 0.052000 -0.45068 0.554679  
60 mg/ml 120 mg/ml 0.031667 -0.47101 0.534346  
140 mg/ml 100 mg/ml 0.024000 -0.47868 0.526679  
 
 
Fit Y by X Group 
Oneway Analysis of Day 7 by PDO scaffolds of varying concentration for aFGF secretion 
 
 
 
Missing Rows 
1 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.55539 0.05 
 
Abs(Dif)-LSD TCP 120 mg/ml 140 mg/ml 80 mg/ml 60 mg/ml 100 mg/ml Media 
TCP -0.48520 -0.27559 -0.26892 -0.21492 -0.20292 -0.20259 -0.29824 
120 mg/ml -0.27559 -0.39616 -0.38950 -0.33550 -0.32350 -0.32316 -0.43159 
140 mg/ml -0.26892 -0.38950 -0.39616 -0.34216 -0.33016 -0.32983 -0.43826 
80 mg/ml -0.21492 -0.33550 -0.34216 -0.39616 -0.38416 -0.38383 -0.49226 
60 mg/ml -0.20292 -0.32350 -0.33016 -0.38416 -0.39616 -0.39583 -0.50426 
100 mg/ml -0.20259 -0.32316 -0.32983 -0.38383 -0.39583 -0.39616 -0.50459 
Media -0.29824 -0.43159 -0.43826 -0.49226 -0.50426 -0.50459 -0.68617 
 
Positive values show pairs of means that are significantly different. 
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Level  Mean 
TCP A 0.42000000 
120 mg/ml A 0.25266667 
140 mg/ml A 0.24600000 
80 mg/ml A 0.19200000 
60 mg/ml A 0.18000000 
100 mg/ml A 0.17966667 
Media A 0.12400000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
TCP Media 0.2960000 -0.298243 0.8902432  
TCP 100 mg/ml 0.2403333 -0.202589 0.6832560  
TCP 60 mg/ml 0.2400000 -0.202923 0.6829227  
TCP 80 mg/ml 0.2280000 -0.214923 0.6709227  
TCP 140 mg/ml 0.1740000 -0.268923 0.6169227  
TCP 120 mg/ml 0.1673333 -0.275589 0.6102560  
120 mg/ml Media 0.1286667 -0.431591 0.6889245  
140 mg/ml Media 0.1220000 -0.438258 0.6822578  
120 mg/ml 100 mg/ml 0.0730000 -0.323162 0.4691621  
120 mg/ml 60 mg/ml 0.0726667 -0.323495 0.4688288  
80 mg/ml Media 0.0680000 -0.492258 0.6282578  
140 mg/ml 100 mg/ml 0.0663333 -0.329829 0.4624954  
140 mg/ml 60 mg/ml 0.0660000 -0.330162 0.4621621  
120 mg/ml 80 mg/ml 0.0606667 -0.335495 0.4568288  
60 mg/ml Media 0.0560000 -0.504258 0.6162578  
100 mg/ml Media 0.0556667 -0.504591 0.6159245  
140 mg/ml 80 mg/ml 0.0540000 -0.342162 0.4501621  
80 mg/ml 100 mg/ml 0.0123333 -0.383829 0.4084954  
80 mg/ml 60 mg/ml 0.0120000 -0.384162 0.4081621  
120 mg/ml 140 mg/ml 0.0066667 -0.389495 0.4028288  
60 mg/ml 100 mg/ml 0.0003333 -0.395829 0.3964954  
 
Oneway Analysis of Day 14 by PDO scaffolds of varying concentration for aFGF secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
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q* Alpha 
 
 
Abs(Dif)-LSD 80 mg/ml 120 mg/ml 100 mg/ml 140 mg/ml 60 mg/ml TCP Media 
80 mg/ml -0.18488 -0.03221 -0.01654 0.00979 0.07679 0.16212 0.09155 
120 mg/ml -0.03221 -0.18488 -0.16921 -0.14288 -0.07588 0.00946 -0.06112 
100 mg/ml -0.01654 -0.16921 -0.18488 -0.15854 -0.09154 -0.00621 -0.07679 
140 mg/ml 0.00979 -0.14288 -0.15854 -0.18488 -0.11788 -0.03254 -0.10312 
60 mg/ml 0.07679 -0.07588 -0.09154 -0.11788 -0.18488 -0.09954 -0.17012 
TCP 0.16212 0.00946 -0.00621 -0.03254 -0.09954 -0.18488 -0.25545 
Media 0.09155 -0.06112 -0.07679 -0.10312 -0.17012 -0.25545 -0.32021 
 
Positive values show pairs of means that are significantly different. 
 
 
Level    Mean 
80 mg/ml A     0.47700000 
120 mg/ml A B   0.32433333 
100 mg/ml A B C 0.30866667 
140 mg/ml   B C 0.28233333 
60 mg/ml   B C 0.21533333 
TCP     C 0.13000000 
Media   B C 0.12400000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
80 mg/ml Media 0.3530000 0.091546 0.6144540  
80 mg/ml TCP 0.3470000 0.162124 0.5318759  
80 mg/ml 60 mg/ml 0.2616667 0.076791 0.4465426  
120 mg/ml Media 0.2003333 -0.061121 0.4617873  
80 mg/ml 140 mg/ml 0.1946667 0.009791 0.3795426  
120 mg/ml TCP 0.1943333 0.009457 0.3792092  
100 mg/ml Media 0.1846667 -0.076787 0.4461207  
100 mg/ml TCP 0.1786667 -0.006209 0.3635426  
80 mg/ml 100 mg/ml 0.1683333 -0.016543 0.3532092  
140 mg/ml Media 0.1583333 -0.103121 0.4197873  
80 mg/ml 120 mg/ml 0.1526667 -0.032209 0.3375426  
140 mg/ml TCP 0.1523333 -0.032543 0.3372092  
120 mg/ml 60 mg/ml 0.1090000 -0.075876 0.2938759  
100 mg/ml 60 mg/ml 0.0933333 -0.091543 0.2782092  
60 mg/ml Media 0.0913333 -0.170121 0.3527873  
60 mg/ml TCP 0.0853333 -0.099543 0.2702092  
140 mg/ml 60 mg/ml 0.0670000 -0.117876 0.2518759  
120 mg/ml 140 mg/ml 0.0420000 -0.142876 0.2268759  
100 mg/ml 140 mg/ml 0.0263333 -0.158543 0.2112092  
120 mg/ml 100 mg/ml 0.0156667 -0.169209 0.2005426  
TCP Media 0.0060000 -0.255454 0.2674540  
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Oneway Analysis of Day 21 by PDO scaffolds of varying concentration for aFGF secretion 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD 140 mg/ml 80 mg/ml 120 mg/ml 60 mg/ml 100 mg/ml TCP Media 
140 mg/ml -0.17096 -0.15763 -0.13596 -0.04663 0.01804 0.04104 0.06522 
80 mg/ml -0.15763 -0.17096 -0.14930 -0.05996 0.00470 0.02770 0.05189 
120 mg/ml -0.13596 -0.14930 -0.17096 -0.08163 -0.01696 0.00604 0.03022 
60 mg/ml -0.04663 -0.05996 -0.08163 -0.17096 -0.10630 -0.08330 -0.05911 
100 mg/ml 0.01804 0.00470 -0.01696 -0.10630 -0.17096 -0.14796 -0.12378 
TCP 0.04104 0.02770 0.00604 -0.08330 -0.14796 -0.17096 -0.14678 
Media 0.06522 0.05189 0.03022 -0.05911 -0.12378 -0.14678 -0.29612 
 
Positive values show pairs of means that are significantly different. 
 
 
Level    Mean 
140 mg/ml A     0.43100000 
80 mg/ml A     0.41766667 
120 mg/ml A B   0.39600000 
60 mg/ml A B C 0.30666667 
100 mg/ml   B C 0.24200000 
TCP     C 0.21900000 
Media     C 0.12400000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
140 mg/ml Media 0.3070000 0.065221 0.5487786  
80 mg/ml Media 0.2936667 0.051888 0.5354453  
120 mg/ml Media 0.2720000 0.030221 0.5137786  
140 mg/ml TCP 0.2120000 0.041037 0.3829633  
80 mg/ml TCP 0.1986667 0.027703 0.3696300  
140 mg/ml 100 mg/ml 0.1890000 0.018037 0.3599633  
60 mg/ml Media 0.1826667 -0.059112 0.4244453  
120 mg/ml TCP 0.1770000 0.006037 0.3479633  
80 mg/ml 100 mg/ml 0.1756667 0.004703 0.3466300  
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Level  - Level Difference Lower CL Upper CL Difference 
120 mg/ml 100 mg/ml 0.1540000 -0.016963 0.3249633  
140 mg/ml 60 mg/ml 0.1243333 -0.046630 0.2952966  
100 mg/ml Media 0.1180000 -0.123779 0.3597786  
80 mg/ml 60 mg/ml 0.1110000 -0.059963 0.2819633  
TCP Media 0.0950000 -0.146779 0.3367786  
120 mg/ml 60 mg/ml 0.0893333 -0.081630 0.2602966  
60 mg/ml TCP 0.0876667 -0.083297 0.2586300  
60 mg/ml 100 mg/ml 0.0646667 -0.106297 0.2356300  
140 mg/ml 120 mg/ml 0.0350000 -0.135963 0.2059633  
100 mg/ml TCP 0.0230000 -0.147963 0.1939633  
80 mg/ml 120 mg/ml 0.0216667 -0.149297 0.1926300  
140 mg/ml 80 mg/ml 0.0133333 -0.157630 0.1842966  
 
Oneway Analysis of Day 28 by PDO scaffolds of varying concentration for aFGF secretion 
 
 
 
Missing Rows 
1 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.55539 0.05 
 
Abs(Dif)-LSD 140 mg/ml 120 mg/ml TCP 100 mg/ml 80 mg/ml 60 mg/ml Media 
140 mg/ml -0.56167 -0.52034 -0.43200 -0.42300 -0.44146 -0.36300 -0.54332 
120 mg/ml -0.52034 -0.56167 -0.47334 -0.46434 -0.48280 -0.40434 -0.58465 
TCP -0.43200 -0.47334 -0.56167 -0.55267 -0.57113 -0.49267 -0.67299 
100 mg/ml -0.42300 -0.46434 -0.55267 -0.56167 -0.58013 -0.50167 -0.68199 
80 mg/ml -0.44146 -0.48280 -0.57113 -0.58013 -0.68790 -0.61580 -0.77800 
60 mg/ml -0.36300 -0.40434 -0.49267 -0.50167 -0.61580 -0.56167 -0.74199 
Media -0.54332 -0.58465 -0.67299 -0.68199 -0.77800 -0.74199 -0.97284 
 
Positive values show pairs of means that are significantly different. 
 
 
Level  Mean 
140 mg/ml A 0.37500000 
120 mg/ml A 0.33366667 
TCP A 0.24533333 
100 mg/ml A 0.23633333 
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Level  Mean 
80 mg/ml A 0.18850000 
60 mg/ml A 0.17633333 
Media A 0.12400000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
140 mg/ml Media 0.2510000 -0.543320 1.045320  
120 mg/ml Media 0.2096667 -0.584653 1.003987  
140 mg/ml 60 mg/ml 0.1986667 -0.363002 0.760336  
140 mg/ml 80 mg/ml 0.1865000 -0.441465 0.814465  
120 mg/ml 60 mg/ml 0.1573333 -0.404336 0.719002  
120 mg/ml 80 mg/ml 0.1451667 -0.482798 0.773132  
140 mg/ml 100 mg/ml 0.1386667 -0.423002 0.700336  
140 mg/ml TCP 0.1296667 -0.432002 0.691336  
TCP Media 0.1213333 -0.672987 0.915653  
100 mg/ml Media 0.1123333 -0.681987 0.906653  
120 mg/ml 100 mg/ml 0.0973333 -0.464336 0.659002  
120 mg/ml TCP 0.0883333 -0.473336 0.650002  
TCP 60 mg/ml 0.0690000 -0.492669 0.630669  
80 mg/ml Media 0.0645000 -0.778003 0.907003  
100 mg/ml 60 mg/ml 0.0600000 -0.501669 0.621669  
TCP 80 mg/ml 0.0568333 -0.571132 0.684798  
60 mg/ml Media 0.0523333 -0.741987 0.846653  
100 mg/ml 80 mg/ml 0.0478333 -0.580132 0.675798  
140 mg/ml 120 mg/ml 0.0413333 -0.520336 0.603002  
80 mg/ml 60 mg/ml 0.0121667 -0.615798 0.640132  
TCP 100 mg/ml 0.0090000 -0.552669 0.570669  
 
 
 
Fit Y by X Group 
Oneway Analysis of Day 7 By PDO scaffolds of varying concentration for TGF-β1 secretion 
 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
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q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD TCP 120 mg/ml Media 80 mg/ml 60 mg/ml 140 mg/ml 100 mg/ml 
TCP -32.505 -28.787 -35.204 -13.747 -13.405 -13.104 -8.029 
120 mg/ml -28.787 -32.505 -38.922 -17.465 -17.123 -16.822 -11.747 
Media -35.204 -38.922 -56.301 -37.977 -37.635 -37.333 -32.258 
80 mg/ml -13.747 -17.465 -37.977 -32.505 -32.163 -31.862 -26.787 
60 mg/ml -13.405 -17.123 -37.635 -32.163 -32.505 -32.204 -27.129 
140 mg/ml -13.104 -16.822 -37.333 -31.862 -32.204 -32.505 -27.430 
100 mg/ml -8.029 -11.747 -32.258 -26.787 -27.129 -27.430 -32.505 
 
Positive values show pairs of means that are significantly different. 
 
 
Level  Mean 
TCP A 36.930333 
120 mg/ml A 33.212000 
Media A 26.165000 
80 mg/ml A 18.172333 
60 mg/ml A 17.830333 
140 mg/ml A 17.529000 
100 mg/ml A 12.454000 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
TCP 100 mg/ml 24.47633 -8.0288 56.98144  
120 mg/ml 100 mg/ml 20.75800 -11.7471 53.26311  
TCP 140 mg/ml 19.40133 -13.1038 51.90644  
TCP 60 mg/ml 19.10000 -13.4051 51.60511  
TCP 80 mg/ml 18.75800 -13.7471 51.26311  
120 mg/ml 140 mg/ml 15.68300 -16.8221 48.18811  
120 mg/ml 60 mg/ml 15.38167 -17.1234 47.88678  
120 mg/ml 80 mg/ml 15.03967 -17.4654 47.54478  
Media 100 mg/ml 13.71100 -32.2582 59.68017  
TCP Media 10.76533 -35.2038 56.73450  
Media 140 mg/ml 8.63600 -37.3332 54.60517  
Media 60 mg/ml 8.33467 -37.6345 54.30384  
Media 80 mg/ml 7.99267 -37.9765 53.96184  
120 mg/ml Media 7.04700 -38.9222 53.01617  
80 mg/ml 100 mg/ml 5.71833 -26.7868 38.22344  
60 mg/ml 100 mg/ml 5.37633 -27.1288 37.88144  
140 mg/ml 100 mg/ml 5.07500 -27.4301 37.58011  
TCP 120 mg/ml 3.71833 -28.7868 36.22344  
80 mg/ml 140 mg/ml 0.64333 -31.8618 33.14844  
80 mg/ml 60 mg/ml 0.34200 -32.1631 32.84711  
60 mg/ml 140 mg/ml 0.30133 -32.2038 32.80644  
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Oneway Analysis of Day 14 By PDO scaffolds of varying concentration for TGF-β1 secretion 
 
 
 
Missing Rows 
1 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.55539 0.05 
 
Abs(Dif)-LSD 140 mg/ml TCP 80 mg/ml 100 mg/ml 120 mg/ml Media 60 mg/ml 
140 mg/ml -33.133 -32.351 -21.775 -21.320 -22.955 -24.467 -8.921 
TCP -32.351 -33.133 -22.557 -22.102 -23.737 -25.249 -9.702 
80 mg/ml -21.775 -22.557 -33.133 -32.678 -34.312 -35.824 -20.278 
100 mg/ml -21.320 -22.102 -32.678 -33.133 -34.767 -36.279 -20.733 
120 mg/ml -22.955 -23.737 -34.312 -34.767 -40.579 -41.398 -26.920 
Media -24.467 -25.249 -35.824 -36.279 -41.398 -57.388 -45.034 
60 mg/ml -8.921 -9.702 -20.278 -20.733 -26.920 -45.034 -33.133 
 
Positive values show pairs of means that are significantly different. 
 
 
Level  Mean 
140 mg/ml A 48.554667 
TCP A 47.773000 
80 mg/ml A 37.197333 
100 mg/ml A 36.742333 
120 mg/ml A 34.466000 
Media A 26.165000 
60 mg/ml A 24.342667 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
140 mg/ml 60 mg/ml 24.21200 -8.9207 57.34473  
TCP 60 mg/ml 23.43033 -9.7024 56.56306  
140 mg/ml Media 22.38967 -24.4671 69.24642  
TCP Media 21.60800 -25.2487 68.46475  
140 mg/ml 120 mg/ml 14.08867 -22.9548 51.13218  
TCP 120 mg/ml 13.30700 -23.7365 50.35051  
80 mg/ml 60 mg/ml 12.85467 -20.2781 45.98739  
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Level  - Level Difference Lower CL Upper CL Difference 
100 mg/ml 60 mg/ml 12.39967 -20.7331 45.53239  
140 mg/ml 100 mg/ml 11.81233 -21.3204 44.94506  
140 mg/ml 80 mg/ml 11.35733 -21.7754 44.49006  
80 mg/ml Media 11.03233 -35.8244 57.88908  
TCP 100 mg/ml 11.03067 -22.1021 44.16339  
100 mg/ml Media 10.57733 -36.2794 57.43408  
TCP 80 mg/ml 10.57567 -22.5571 43.70839  
120 mg/ml 60 mg/ml 10.12333 -26.9202 47.16685  
120 mg/ml Media 8.30100 -41.3981 58.00009  
80 mg/ml 120 mg/ml 2.73133 -34.3122 39.77485  
100 mg/ml 120 mg/ml 2.27633 -34.7672 39.31985  
Media 60 mg/ml 1.82233 -45.0344 48.67908  
140 mg/ml TCP 0.78167 -32.3511 33.91439  
80 mg/ml 100 mg/ml 0.45500 -32.6777 33.58773  
 
Oneway Analysis of Day 21 By PDO scaffolds of varying concentration for TGF-β1 secretion 
 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
 
Abs(Dif)-LSD 80 mg/ml 100 mg/ml Media 60 mg/ml 140 mg/ml 120 mg/ml TCP 
80 mg/ml -33.333 -15.219 -19.427 2.962 6.130 7.105 9.451 
100 mg/ml -15.219 -33.333 -37.540 -15.152 -11.983 -11.008 -8.663 
Media -19.427 -37.540 -57.734 -38.558 -35.390 -34.415 -32.069 
60 mg/ml 2.962 -15.152 -38.558 -33.333 -30.164 -29.189 -26.844 
140 mg/ml 6.130 -11.983 -35.390 -30.164 -33.333 -32.358 -30.012 
120 mg/ml 7.105 -11.008 -34.415 -29.189 -32.358 -33.333 -30.987 
TCP 9.451 -8.663 -32.069 -26.844 -30.012 -30.987 -33.333 
 
Positive values show pairs of means that are significantly different. 
 
 
Level   Mean 
80 mg/ml A   53.878000 
100 mg/ml A B 35.764667 
Media A B 26.165000 
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Level   Mean 
60 mg/ml   B 17.583667 
140 mg/ml   B 14.415000 
120 mg/ml   B 13.440000 
TCP   B 11.094667 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
80 mg/ml TCP 42.78333 9.4506 76.11611  
80 mg/ml 120 mg/ml 40.43800 7.1052 73.77078  
80 mg/ml 140 mg/ml 39.46300 6.1302 72.79578  
80 mg/ml 60 mg/ml 36.29433 2.9616 69.62711  
80 mg/ml Media 27.71300 -19.4267 74.85267  
100 mg/ml TCP 24.67000 -8.6628 58.00278  
100 mg/ml 120 mg/ml 22.32467 -11.0081 55.65744  
100 mg/ml 140 mg/ml 21.34967 -11.9831 54.68244  
100 mg/ml 60 mg/ml 18.18100 -15.1518 51.51378  
80 mg/ml 100 mg/ml 18.11333 -15.2194 51.44611  
Media TCP 15.07033 -32.0693 62.21000  
Media 120 mg/ml 12.72500 -34.4147 59.86467  
Media 140 mg/ml 11.75000 -35.3897 58.88967  
100 mg/ml Media 9.59967 -37.5400 56.73933  
Media 60 mg/ml 8.58133 -38.5583 55.72100  
60 mg/ml TCP 6.48900 -26.8438 39.82178  
60 mg/ml 120 mg/ml 4.14367 -29.1891 37.47644  
140 mg/ml TCP 3.32033 -30.0124 36.65311  
60 mg/ml 140 mg/ml 3.16867 -30.1641 36.50144  
120 mg/ml TCP 2.34533 -30.9874 35.67811  
140 mg/ml 120 mg/ml 0.97500 -32.3578 34.30778  
 
Oneway Analysis of Day 28 By PDO scaffolds of varying concentration for TGF-β1 secretion 
 
 
 
 
Means Comparisons 
Comparisons for all pairs using Tukey-Kramer HSD 
q* Alpha 
3.49978 0.05 
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Abs(Dif)-LSD 100 mg/ml 140 mg/ml 120 mg/ml Media 60 mg/ml TCP 80 mg/ml 
100 mg/ml -21.200 -7.652 -2.310 2.596 16.889 20.056 24.735 
140 mg/ml -7.652 -21.200 -15.859 -10.952 3.340 6.507 11.187 
120 mg/ml -2.310 -15.859 -21.200 -16.294 -2.001 1.166 5.845 
Media 2.596 -10.952 -16.294 -36.720 -24.471 -21.304 -16.625 
60 mg/ml 16.889 3.340 -2.001 -24.471 -21.200 -18.033 -13.354 
TCP 20.056 6.507 1.166 -21.304 -18.033 -21.200 -16.521 
80 mg/ml 24.735 11.187 5.845 -16.625 -13.354 -16.521 -21.200 
 
Positive values show pairs of means that are significantly different. 
 
 
Level     Mean 
100 mg/ml A       58.743333 
140 mg/ml A B     45.194667 
120 mg/ml A B C   39.853333 
Media   B C D 26.165000 
60 mg/ml     C D 20.654000 
TCP       D 17.487000 
80 mg/ml       D 12.807667 
 
Levels not connected by same letter are significantly different. 
 
Level  - Level Difference Lower CL Upper CL Difference 
100 mg/ml 80 mg/ml 45.93567 24.7352 67.13612  
100 mg/ml TCP 41.25633 20.0559 62.45679  
100 mg/ml 60 mg/ml 38.08933 16.8889 59.28979  
100 mg/ml Media 32.57833 2.5964 62.56030  
140 mg/ml 80 mg/ml 32.38700 11.1865 53.58745  
140 mg/ml TCP 27.70767 6.5072 48.90812  
120 mg/ml 80 mg/ml 27.04567 5.8452 48.24612  
140 mg/ml 60 mg/ml 24.54067 3.3402 45.74112  
120 mg/ml TCP 22.36633 1.1659 43.56679  
120 mg/ml 60 mg/ml 19.19933 -2.0011 40.39979  
140 mg/ml Media 19.02967 -10.9523 49.01164  
100 mg/ml 120 mg/ml 18.89000 -2.3105 40.09045  
120 mg/ml Media 13.68833 -16.2936 43.67030  
100 mg/ml 140 mg/ml 13.54867 -7.6518 34.74912  
Media 80 mg/ml 13.35733 -16.6246 43.33930  
Media TCP 8.67800 -21.3040 38.65997  
60 mg/ml 80 mg/ml 7.84633 -13.3541 29.04679  
Media 60 mg/ml 5.51100 -24.4710 35.49297  
140 mg/ml 120 mg/ml 5.34133 -15.8591 26.54179  
TCP 80 mg/ml 4.67933 -16.5211 25.87979  
60 mg/ml TCP 3.16700 -18.0335 24.36745  
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